'sentence': Association of alcohol dependence ( AD ) with markers located at the 3 ' region of GABRA 2 has been replicated in several studies , but recent studies suggested the possibility that the signal may be attributable to the adjacent gene , GABRG 1 , located 90 kb distant in the 3 ' direction .,
                    'spans': [([2], '<<chemical>>'), ([2, 3], '<<disease>>'), ([5], '<<disease>>'), ([12, 13, 14, 15, 16, 17], '<<genomic_factor>>'), ([16, 17], '<<gene_or_protein>>'), ([42, 43], '<<gene_or_protein>>')],
                    'pred_spans': [([2], '<<chemical>>'), ([2, 3], '<<disease>>'), ([5], '<<disease>>'), ([8, 9, 10, 11, 12, 13, 14, 15, 16, 17], '<<limited_variation>>'), ([12, 13, 14, 15, 16, 17], '<<genomic_factor>>'), ([16, 17], '<<gene_or_protein>>'), ([42, 43], '<<gene_or_protein>>')],
                    'entities' : ['alcohol <<chemical>>', 'alcohol dependence <<disease>>', 'AD <<disease>>', "3 ' region of GABRA 2 <<genomic_factor>>", 'GABRA 2 <<gene_or_protein>>', 'GABRG 1 <<gene_or_protein>>'],
                    'pred_entities' : ['alcohol <<chemical>>', 'alcohol dependence <<disease>>', 'AD <<disease>>', "markers located at the 3 ' region of GABRA 2 <<limited_variation>>", "3 ' region of GABRA 2 <<genomic_factor>>", 'GABRA 2 <<gene_or_protein>>', 'GABRG 1 <<gene_or_protein>>'] 

'sentence': Most GISTs respond to imatinib mesylate , which selectively inhibits both KIT and PDGFRA , and is now considered as the standard systemic therapy for advanced GIST .,
                    'spans': [([1], '<<disease>>'), ([4, 5], '<<chemical>>'), ([11], '<<gene_or_protein>>'), ([13], '<<gene_or_protein>>'), ([26], '<<disease>>')],
                    'pred_spans': [([1], '<<disease>>'), ([4, 5], '<<chemical>>'), ([11], '<<gene_or_protein>>'), ([13], '<<gene_or_protein>>'), ([26], '<<disease>>')],
                    'entities' : ['GISTs <<disease>>', 'imatinib mesylate <<chemical>>', 'KIT <<gene_or_protein>>', 'PDGFRA <<gene_or_protein>>', 'GIST <<disease>>'],
                    'pred_entities' : ['GISTs <<disease>>', 'imatinib mesylate <<chemical>>', 'KIT <<gene_or_protein>>', 'PDGFRA <<gene_or_protein>>', 'GIST <<disease>>'] 

'sentence': The angiotensin II - AT 1 receptor antagonist , losartan , applied intracerebroventricular five minutes prior to angiotensin II , prevented the angiotensin II - induced immediate early gene protein expression .,
                    'spans': [([1, 2, 3, 4, 5, 6], '<<gene_or_protein>>'), ([1, 2, 3, 4, 5, 6, 7], '<<chemical>>'), ([9], '<<chemical>>'), ([17, 18], '<<chemical>>'), ([22, 23], '<<chemical>>'), ([22, 23, 24, 25, 26, 27, 28, 29, 30], '<<pharmacodynamic_phenotype>>'), ([26, 27, 28, 29, 30], '<<pharmacodynamic_phenotype>>')],
                    'pred_spans': [([1, 2], '<<gene_or_protein>>'), ([1, 2, 3, 4, 5, 6, 7], '<<chemical>>'), ([9], '<<chemical>>'), ([17, 18], '<<chemical>>'), ([22, 23, 24, 25, 26, 27, 28, 29, 30], '<<pharmacodynamic_phenotype>>'), ([26, 27, 28, 29, 30], '<<phenotype>>')],
                    'entities' : ['angiotensin II - AT 1 receptor <<gene_or_protein>>', 'angiotensin II - AT 1 receptor antagonist <<chemical>>', 'losartan <<chemical>>', 'angiotensin II <<chemical>>', 'angiotensin II <<chemical>>', 'angiotensin II - induced immediate early gene protein expression <<pharmacodynamic_phenotype>>', 'immediate early gene protein expression <<pharmacodynamic_phenotype>>'],
                    'pred_entities' : ['angiotensin II <<gene_or_protein>>', 'angiotensin II - AT 1 receptor antagonist <<chemical>>', 'losartan <<chemical>>', 'angiotensin II <<chemical>>', 'angiotensin II - induced immediate early gene protein expression <<pharmacodynamic_phenotype>>', 'immediate early gene protein expression <<phenotype>>'] 

'sentence': The levels of c - fos , c - jun and rsGFP mRNA , as well as the levels of rsGFP protein , in the FR - pQBI 25 cells were found to be significantly higher following exposure to doxorubicin .,
                    'spans': [([1, 2, 3, 4, 5, 12], '<<phenotype>>'), ([1, 2, 7, 8, 9, 12], '<<phenotype>>'), ([1, 2, 11, 12], '<<phenotype>>'), ([3, 4, 5], '<<gene_or_protein>>'), ([3, 4, 5, 12], '<<genomic_factor>>'), ([7, 8, 9], '<<gene_or_protein>>'), ([7, 8, 9, 12], '<<genomic_factor>>'), ([11], '<<gene_or_protein>>'), ([11, 12], '<<genomic_factor>>'), ([18, 19, 20, 21], '<<phenotype>>'), ([20], '<<gene_or_protein>>'), ([39], '<<chemical>>')],
                    'pred_spans': [([1, 2, 3, 4, 5], '<<phenotype>>'), ([1, 2, 7, 8, 9], '<<phenotype>>'), ([1, 2, 11, 12], '<<phenotype>>'), ([3, 4, 5], '<<gene_or_protein>>'), ([7, 8, 9], '<<gene_or_protein>>'), ([11], '<<gene_or_protein>>'), ([11, 12], '<<genomic_factor>>'), ([18, 19, 20, 21], '<<phenotype>>'), ([20], '<<gene_or_protein>>'), ([39], '<<chemical>>')],
                    'entities' : ['levels of c - fos mRNA <<phenotype>>', 'levels of c - jun mRNA <<phenotype>>', 'levels of rsGFP mRNA <<phenotype>>', 'c - fos <<gene_or_protein>>', 'c - fos mRNA <<genomic_factor>>', 'c - jun <<gene_or_protein>>', 'c - jun mRNA <<genomic_factor>>', 'rsGFP <<gene_or_protein>>', 'rsGFP mRNA <<genomic_factor>>', 'levels of rsGFP protein <<phenotype>>', 'rsGFP <<gene_or_protein>>', 'doxorubicin <<chemical>>'],
                    'pred_entities' : ['levels of c - fos <<phenotype>>', 'levels of c - jun <<phenotype>>', 'levels of rsGFP mRNA <<phenotype>>', 'c - fos <<gene_or_protein>>', 'c - jun <<gene_or_protein>>', 'rsGFP <<gene_or_protein>>', 'rsGFP mRNA <<genomic_factor>>', 'levels of rsGFP protein <<phenotype>>', 'rsGFP <<gene_or_protein>>', 'doxorubicin <<chemical>>'] 

'sentence': Although morphine and heroin analgesia is mediated by mu - opioid receptors encoded by the MOR - 1 gene , distinct isoforms are involved .,
                    'spans': [([1], '<<chemical>>'), ([1, 4], '<<pharmacodynamic_phenotype>>'), ([3], '<<chemical>>'), ([3, 4], '<<pharmacodynamic_phenotype>>'), ([8, 9, 10, 11], '<<gene_or_protein>>'), ([15, 16, 17], '<<gene_or_protein>>')],
                    'pred_spans': [([1], '<<chemical>>'), ([1, 4], '<<pharmacodynamic_phenotype>>'), ([3], '<<chemical>>'), ([3, 4], '<<pharmacodynamic_phenotype>>'), ([8, 9, 10, 11], '<<gene_or_protein>>'), ([15, 16, 17], '<<gene_or_protein>>')],
                    'entities' : ['morphine <<chemical>>', 'morphine analgesia <<pharmacodynamic_phenotype>>', 'heroin <<chemical>>', 'heroin analgesia <<pharmacodynamic_phenotype>>', 'mu - opioid receptors <<gene_or_protein>>', 'MOR - 1 <<gene_or_protein>>'],
                    'pred_entities' : ['morphine <<chemical>>', 'morphine analgesia <<pharmacodynamic_phenotype>>', 'heroin <<chemical>>', 'heroin analgesia <<pharmacodynamic_phenotype>>', 'mu - opioid receptors <<gene_or_protein>>', 'MOR - 1 <<gene_or_protein>>'] 

'sentence': In the present study , a potential relationship between T 102 C polymorphism in the 5 - HT receptor subtype 2 A gene ( HTR 2 A ) and alcohol dependence was examined .,
                    'spans': [([9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], '<<limited_variation>>'), ([15, 16, 17, 18, 19, 20, 21], '<<gene_or_protein>>'), ([24, 25, 26], '<<gene_or_protein>>'), ([29], '<<chemical>>'), ([29, 30], '<<disease>>')],
                    'pred_spans': [([9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], '<<limited_variation>>'), ([15, 16, 17, 18], '<<gene_or_protein>>'), ([15, 16, 17, 18, 19, 20, 21], '<<gene_or_protein>>'), ([24, 25, 26], '<<gene_or_protein>>'), ([29], '<<chemical>>'), ([29, 30], '<<disease>>')],
                    'entities' : ['T 102 C polymorphism in the 5 - HT receptor subtype 2 A gene ( HTR 2 A ) <<limited_variation>>', '5 - HT receptor subtype 2 A <<gene_or_protein>>', 'HTR 2 A <<gene_or_protein>>', 'alcohol <<chemical>>', 'alcohol dependence <<disease>>'],
                    'pred_entities' : ['T 102 C polymorphism in the 5 - HT receptor subtype 2 A gene ( HTR 2 A ) <<limited_variation>>', '5 - HT receptor <<gene_or_protein>>', '5 - HT receptor subtype 2 A <<gene_or_protein>>', 'HTR 2 A <<gene_or_protein>>', 'alcohol <<chemical>>', 'alcohol dependence <<disease>>'] 

'sentence': This patient had an excellent response to Icotinib but not crizotinib , suggesting that the EGFR mutation was the oncogenic driver but ROS 1 fusion and KRAS mutation not .,
                    'spans': [([5, 6, 7], '<<pharmacodynamic_phenotype>>'), ([5, 6, 10], '<<pharmacodynamic_phenotype>>'), ([7], '<<chemical>>'), ([10], '<<chemical>>'), ([15], '<<gene_or_protein>>'), ([15, 16], '<<limited_variation>>'), ([22, 23], '<<gene_or_protein>>'), ([22, 23, 24], '<<genomic_factor>>'), ([26], '<<gene_or_protein>>'), ([26, 27], '<<limited_variation>>')],
                    'pred_spans': [([5, 6, 7], '<<pharmacodynamic_phenotype>>'), ([5, 6, 10], '<<pharmacodynamic_phenotype>>'), ([7], '<<chemical>>'), ([10], '<<chemical>>'), ([15], '<<gene_or_protein>>'), ([15, 16], '<<limited_variation>>'), ([22, 23], '<<gene_or_protein>>'), ([22, 23, 24], '<<limited_variation>>'), ([26], '<<gene_or_protein>>'), ([26, 27], '<<limited_variation>>')],
                    'entities' : ['response to Icotinib <<pharmacodynamic_phenotype>>', 'response to crizotinib <<pharmacodynamic_phenotype>>', 'Icotinib <<chemical>>', 'crizotinib <<chemical>>', 'EGFR <<gene_or_protein>>', 'EGFR mutation <<limited_variation>>', 'ROS 1 <<gene_or_protein>>', 'ROS 1 fusion <<genomic_factor>>', 'KRAS <<gene_or_protein>>', 'KRAS mutation <<limited_variation>>'],
                    'pred_entities' : ['response to Icotinib <<pharmacodynamic_phenotype>>', 'response to crizotinib <<pharmacodynamic_phenotype>>', 'Icotinib <<chemical>>', 'crizotinib <<chemical>>', 'EGFR <<gene_or_protein>>', 'EGFR mutation <<limited_variation>>', 'ROS 1 <<gene_or_protein>>', 'ROS 1 fusion <<limited_variation>>', 'KRAS <<gene_or_protein>>', 'KRAS mutation <<limited_variation>>'] 

'sentence': However , in patients who were co - administered AZ , the C 0 values of tacrolimus were higher in patients with the CYP 3 A 5 * 3 / * 3 allele than with the CYP 3 A 5 * 1 allele ( P = 0 . 034 ) , although daily doses of Tac - QD in patients with CYP 3 A 5 * 3 / * 3 were significantly lower than those with the CYP 3 A 5 * 1 allele ( P = 0 . 041 ) .,
                    'spans': [([9], '<<chemical>>'), ([12, 13, 14, 15, 16], '<<pharmacodynamic_phenotype>>'), ([16], '<<chemical>>'), ([23, 24, 25, 26], '<<gene_or_protein>>'), ([23, 24, 25, 26, 27, 28, 29, 30, 31], '<<haplotype>>'), ([36, 37, 38, 39], '<<gene_or_protein>>'), ([36, 37, 38, 39, 40, 41], '<<haplotype>>'), ([52, 53, 54, 55, 56, 57], '<<pharmacodynamic_phenotype>>'), ([55, 56, 57], '<<chemical>>'), ([61, 62, 63, 64], '<<gene_or_protein>>'), ([61, 62, 63, 64, 65, 66, 67, 68, 69], '<<haplotype>>'), ([77, 78, 79, 80], '<<gene_or_protein>>'), ([77, 78, 79, 80, 81, 82], '<<haplotype>>')],
                    'pred_spans': [([6, 7, 8, 9], '<<chemical>>'), ([9], '<<chemical>>'), ([12, 13, 14, 15, 16], '<<pharmacodynamic_phenotype>>'), ([16], '<<chemical>>'), ([23, 24, 25, 26], '<<gene_or_protein>>'), ([23, 24, 25, 26, 27, 28, 29, 30, 31], '<<haplotype>>'), ([36, 37, 38, 39], '<<gene_or_protein>>'), ([36, 37, 38, 39, 40, 41], '<<haplotype>>'), ([52, 53, 54, 55, 56, 57], '<<pharmacodynamic_phenotype>>'), ([55], '<<chemical>>'), ([61, 62, 63, 64], '<<gene_or_protein>>'), ([61, 62, 63, 64, 65, 66, 67, 68, 69], '<<haplotype>>'), ([77, 78, 79, 80], '<<gene_or_protein>>'), ([77, 78, 79, 80, 81, 82, 83], '<<haplotype>>')],
                    'entities' : ['AZ <<chemical>>', 'C 0 values of tacrolimus <<pharmacodynamic_phenotype>>', 'tacrolimus <<chemical>>', 'CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 * 3 / * 3 <<haplotype>>', 'CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 * 1 <<haplotype>>', 'daily doses of Tac - QD <<pharmacodynamic_phenotype>>', 'Tac - QD <<chemical>>', 'CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 * 3 / * 3 <<haplotype>>', 'CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 * 1 <<haplotype>>'],
                    'pred_entities' : ['co - administered AZ <<chemical>>', 'AZ <<chemical>>', 'C 0 values of tacrolimus <<pharmacodynamic_phenotype>>', 'tacrolimus <<chemical>>', 'CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 * 3 / * 3 <<haplotype>>', 'CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 * 1 <<haplotype>>', 'daily doses of Tac - QD <<pharmacodynamic_phenotype>>', 'Tac <<chemical>>', 'CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 * 3 / * 3 <<haplotype>>', 'CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 * 1 allele <<haplotype>>'] 

'sentence': We found that lycopene down - regulates the expression of costimulatory molecules ( CD 80 and CD 86 ) and major histocompatibility complex type II molecules .,
                    'spans': [([3], '<<chemical>>'), ([8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18], '<<phenotype>>'), ([8, 9, 20, 21, 22, 23, 24], '<<phenotype>>'), ([10, 11], '<<gene_or_protein>>'), ([13, 14], '<<gene_or_protein>>'), ([16, 17], '<<gene_or_protein>>'), ([20, 21, 22, 23, 24], '<<gene_or_protein>>')],
                    'pred_spans': [([3], '<<chemical>>'), ([8, 9, 10, 11], '<<phenotype>>'), ([8, 9, 16, 17], '<<phenotype>>'), ([8, 9, 20, 21, 22, 23, 24, 25], '<<phenotype>>'), ([10, 11], '<<gene_or_protein>>'), ([13, 14], '<<gene_or_protein>>'), ([16, 17], '<<gene_or_protein>>'), ([20, 21, 22, 23, 24, 25], '<<gene_or_protein>>')],
                    'entities' : ['lycopene <<chemical>>', 'expression of costimulatory molecules ( CD 80 and CD 86 ) <<phenotype>>', 'expression of major histocompatibility complex type II <<phenotype>>', 'costimulatory molecules <<gene_or_protein>>', 'CD 80 <<gene_or_protein>>', 'CD 86 <<gene_or_protein>>', 'major histocompatibility complex type II <<gene_or_protein>>'],
                    'pred_entities' : ['lycopene <<chemical>>', 'expression of costimulatory molecules <<phenotype>>', 'expression of CD 86 <<phenotype>>', 'expression of major histocompatibility complex type II molecules <<phenotype>>', 'costimulatory molecules <<gene_or_protein>>', 'CD 80 <<gene_or_protein>>', 'CD 86 <<gene_or_protein>>', 'major histocompatibility complex type II molecules <<gene_or_protein>>'] 

'sentence': Cytochrome P 450 2 C 9 ( CYP 2 C 9 ) and vitamin K epoxide reductase ( VKORC 1 ) genotypes as determinants of acenocoumarol sensitivity .,
                    'spans': [([0, 1, 2, 3, 4, 5], '<<gene_or_protein>>'), ([0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 21], '<<limited_variation>>'), ([7, 8, 9, 10], '<<gene_or_protein>>'), ([13, 14, 15, 16], '<<gene_or_protein>>'), ([13, 14, 15, 16, 17, 18, 19, 20, 21], '<<limited_variation>>'), ([18, 19], '<<gene_or_protein>>'), ([25], '<<chemical>>'), ([25, 26], '<<pharmacodynamic_phenotype>>')],
                    'pred_spans': [([0, 1, 2, 3, 4, 5], '<<gene_or_protein>>'), ([0, 8, 9, 10, 21], '<<limited_variation>>'), ([13, 14, 15, 16], '<<gene_or_protein>>'), ([13, 14, 15, 16, 17, 18, 19, 20, 21], '<<limited_variation>>'), ([18, 19], '<<gene_or_protein>>'), ([25], '<<chemical>>'), ([25, 26], '<<pharmacodynamic_phenotype>>')],
                    'entities' : ['Cytochrome P 450 2 C 9 <<gene_or_protein>>', 'Cytochrome P 450 2 C 9 ( CYP 2 C 9 ) genotypes <<limited_variation>>', 'CYP 2 C 9 <<gene_or_protein>>', 'vitamin K epoxide reductase <<gene_or_protein>>', 'vitamin K epoxide reductase ( VKORC 1 ) genotypes <<limited_variation>>', 'VKORC 1 <<gene_or_protein>>', 'acenocoumarol <<chemical>>', 'acenocoumarol sensitivity <<pharmacodynamic_phenotype>>'],
                    'pred_entities' : ['Cytochrome P 450 2 C 9 <<gene_or_protein>>', 'Cytochrome 2 C 9 genotypes <<limited_variation>>', 'vitamin K epoxide reductase <<gene_or_protein>>', 'vitamin K epoxide reductase ( VKORC 1 ) genotypes <<limited_variation>>', 'VKORC 1 <<gene_or_protein>>', 'acenocoumarol <<chemical>>', 'acenocoumarol sensitivity <<pharmacodynamic_phenotype>>'] 

'sentence': We found oral clearance of S - warfarin to be higher among carriers of the minor rs 7089580 allele ( T ) compared with wild - type homozygotes ( 3 . 73 1 . 46 vs 2 . 95 1 . 39 mL / min ; P = 0 . 04 ) .,
                    'spans': [([2, 3, 4, 5, 6, 7], '<<pharmacokinetic_phenotype>>'), ([5, 6, 7], '<<chemical>>'), ([16, 17], '<<limited_variation>>'), ([16, 17, 18, 19, 20, 21], '<<limited_variation>>'), ([24, 25, 26, 27], '<<limited_variation>>')],
                    'pred_spans': [([3, 4, 5, 6, 7], '<<pharmacokinetic_phenotype>>'), ([5, 6, 7], '<<chemical>>'), ([16, 17], '<<limited_variation>>'), ([24, 25, 26, 27], '<<limited_variation>>')],
                    'entities' : ['oral clearance of S - warfarin <<pharmacokinetic_phenotype>>', 'S - warfarin <<chemical>>', 'rs 7089580 <<limited_variation>>', 'rs 7089580 allele ( T ) <<limited_variation>>', 'wild - type homozygotes <<limited_variation>>'],
                    'pred_entities' : ['clearance of S - warfarin <<pharmacokinetic_phenotype>>', 'S - warfarin <<chemical>>', 'rs 7089580 <<limited_variation>>', 'wild - type homozygotes <<limited_variation>>'] 

'sentence': Is there a role for MDR 1 , EPHX 1 and protein Z gene variants in modulation of warfarin dosage ? a study on a cohort of the Egyptian population .,
                    'spans': [([5, 6], '<<gene_or_protein>>'), ([5, 6, 13, 14], '<<limited_variation>>'), ([8, 9], '<<gene_or_protein>>'), ([8, 9, 13, 14], '<<limited_variation>>'), ([11, 12], '<<gene_or_protein>>'), ([11, 12, 13, 14], '<<limited_variation>>'), ([16, 17, 18, 19], '<<pharmacodynamic_phenotype>>'), ([18], '<<chemical>>')],
                    'pred_spans': [([5, 6], '<<gene_or_protein>>'), ([5, 6, 13, 14], '<<limited_variation>>'), ([8, 9], '<<gene_or_protein>>'), ([8, 9, 13, 14], '<<limited_variation>>'), ([11, 12], '<<gene_or_protein>>'), ([11, 12, 13, 14], '<<limited_variation>>'), ([18], '<<chemical>>'), ([18, 19], '<<pharmacodynamic_phenotype>>')],
                    'entities' : ['MDR 1 <<gene_or_protein>>', 'MDR 1 gene variants <<limited_variation>>', 'EPHX 1 <<gene_or_protein>>', 'EPHX 1 gene variants <<limited_variation>>', 'protein Z <<gene_or_protein>>', 'protein Z gene variants <<limited_variation>>', 'modulation of warfarin dosage <<pharmacodynamic_phenotype>>', 'warfarin <<chemical>>'],
                    'pred_entities' : ['MDR 1 <<gene_or_protein>>', 'MDR 1 gene variants <<limited_variation>>', 'EPHX 1 <<gene_or_protein>>', 'EPHX 1 gene variants <<limited_variation>>', 'protein Z <<gene_or_protein>>', 'protein Z gene variants <<limited_variation>>', 'warfarin <<chemical>>', 'warfarin dosage <<pharmacodynamic_phenotype>>'] 

'sentence': RESULTS : Four polymorphisms in CYP 3 A 5 and one polymorphism in CYP 3 A 4 were identified to be significantly associated with tacrolimus stable dose ( p < 8 . 46 10 ( - 5 ) ) .,
                    'spans': [([3, 4, 5, 6, 7, 8], '<<limited_variation>>'), ([5, 6, 7, 8], '<<gene_or_protein>>'), ([11, 12, 13, 14, 15, 16], '<<limited_variation>>'), ([13, 14, 15, 16], '<<gene_or_protein>>'), ([24], '<<chemical>>'), ([24, 25, 26], '<<pharmacodynamic_phenotype>>')],
                    'pred_spans': [([3, 4, 5, 6, 7, 8], '<<limited_variation>>'), ([3, 12, 13, 14, 15, 16], '<<limited_variation>>'), ([5, 6, 7, 8], '<<gene_or_protein>>'), ([11, 12, 13, 14, 15, 16], '<<limited_variation>>'), ([13, 14, 15, 16], '<<gene_or_protein>>'), ([24], '<<chemical>>'), ([24, 25, 26], '<<pharmacodynamic_phenotype>>')],
                    'entities' : ['polymorphisms in CYP 3 A 5 <<limited_variation>>', 'CYP 3 A 5 <<gene_or_protein>>', 'polymorphism in CYP 3 A 4 <<limited_variation>>', 'CYP 3 A 4 <<gene_or_protein>>', 'tacrolimus <<chemical>>', 'tacrolimus stable dose <<pharmacodynamic_phenotype>>'],
                    'pred_entities' : ['polymorphisms in CYP 3 A 5 <<limited_variation>>', 'polymorphisms in CYP 3 A 4 <<limited_variation>>', 'CYP 3 A 5 <<gene_or_protein>>', 'polymorphism in CYP 3 A 4 <<limited_variation>>', 'CYP 3 A 4 <<gene_or_protein>>', 'tacrolimus <<chemical>>', 'tacrolimus stable dose <<pharmacodynamic_phenotype>>'] 

'sentence': Comparison of transformation by manganese sulfate and 5 - azacytidine in Rat 6 cells overexpressing the c - myc oncogene .,
                    'spans': [([2, 3, 4, 5], '<<pharmacodynamic_phenotype>>'), ([2, 3, 7, 8, 9], '<<pharmacodynamic_phenotype>>'), ([4, 5], '<<chemical>>'), ([7, 8, 9], '<<chemical>>'), ([14, 15, 16, 17, 18], '<<phenotype>>'), ([16, 17, 18], '<<gene_or_protein>>')],
                    'pred_spans': [([2, 3, 4, 5], '<<pharmacokinetic_phenotype>>'), ([2, 3, 7, 8, 9], '<<pharmacokinetic_phenotype>>'), ([4, 5], '<<chemical>>'), ([7, 8, 9], '<<chemical>>'), ([14, 15, 16, 17, 18, 19], '<<phenotype>>'), ([16, 17, 18], '<<gene_or_protein>>')],
                    'entities' : ['transformation by manganese sulfate <<pharmacodynamic_phenotype>>', 'transformation by 5 - azacytidine <<pharmacodynamic_phenotype>>', 'manganese sulfate <<chemical>>', '5 - azacytidine <<chemical>>', 'overexpressing the c - myc <<phenotype>>', 'c - myc <<gene_or_protein>>'],
                    'pred_entities' : ['transformation by manganese sulfate <<pharmacokinetic_phenotype>>', 'transformation by 5 - azacytidine <<pharmacokinetic_phenotype>>', 'manganese sulfate <<chemical>>', '5 - azacytidine <<chemical>>', 'overexpressing the c - myc oncogene <<phenotype>>', 'c - myc <<gene_or_protein>>'] 

'sentence': Catechol - O - methyltransferase ( COMT ) catalyzes the breakdown of cerebral dopamine .,
                    'spans': [([0, 1, 2, 3, 4], '<<gene_or_protein>>'), ([6], '<<gene_or_protein>>'), ([10, 11, 12, 13], '<<pharmacokinetic_phenotype>>'), ([13], '<<chemical>>')],
                    'pred_spans': [([0, 1, 2, 3, 4], '<<gene_or_protein>>'), ([6], '<<gene_or_protein>>'), ([10, 11, 12, 13], '<<pharmacokinetic_phenotype>>'), ([13], '<<chemical>>')],
                    'entities' : ['Catechol - O - methyltransferase <<gene_or_protein>>', 'COMT <<gene_or_protein>>', 'breakdown of cerebral dopamine <<pharmacokinetic_phenotype>>', 'dopamine <<chemical>>'],
                    'pred_entities' : ['Catechol - O - methyltransferase <<gene_or_protein>>', 'COMT <<gene_or_protein>>', 'breakdown of cerebral dopamine <<pharmacokinetic_phenotype>>', 'dopamine <<chemical>>'] 

'sentence': The contribution of polymorphism in the alcohol dehydrogenase beta subunit to alcohol sensitivity in a Japanese population .,
                    'spans': [([3, 4, 5, 6, 7, 8, 9], '<<limited_variation>>'), ([6, 7], '<<gene_or_protein>>'), ([6, 7, 8, 9], '<<genomic_factor>>'), ([11], '<<chemical>>'), ([11, 12], '<<pharmacodynamic_phenotype>>')],
                    'pred_spans': [([3, 4, 5, 6, 7, 8, 9], '<<limited_variation>>'), ([6], '<<chemical>>'), ([11, 12], '<<pharmacodynamic_phenotype>>')],
                    'entities' : ['polymorphism in the alcohol dehydrogenase beta subunit <<limited_variation>>', 'alcohol dehydrogenase <<gene_or_protein>>', 'alcohol dehydrogenase beta subunit <<genomic_factor>>', 'alcohol <<chemical>>', 'alcohol sensitivity <<pharmacodynamic_phenotype>>'],
                    'pred_entities' : ['polymorphism in the alcohol dehydrogenase beta subunit <<limited_variation>>', 'alcohol <<chemical>>', 'alcohol sensitivity <<pharmacodynamic_phenotype>>'] 

'sentence': Catechol - O - methyltransferase ( COMT ) is involved in the catabolism of Ecstasy .,
                    'spans': [([0, 1, 2, 3, 4], '<<gene_or_protein>>'), ([6], '<<gene_or_protein>>'), ([12, 13, 14], '<<pharmacokinetic_phenotype>>'), ([14], '<<chemical>>')],
                    'pred_spans': [([0, 1, 2, 3, 4], '<<gene_or_protein>>'), ([6], '<<gene_or_protein>>'), ([12, 13, 14], '<<pharmacokinetic_phenotype>>'), ([14], '<<chemical>>')],
                    'entities' : ['Catechol - O - methyltransferase <<gene_or_protein>>', 'COMT <<gene_or_protein>>', 'catabolism of Ecstasy <<pharmacokinetic_phenotype>>', 'Ecstasy <<chemical>>'],
                    'pred_entities' : ['Catechol - O - methyltransferase <<gene_or_protein>>', 'COMT <<gene_or_protein>>', 'catabolism of Ecstasy <<pharmacokinetic_phenotype>>', 'Ecstasy <<chemical>>'] 

'sentence': The 1976 C > T polymorphism in the adenosine A 2 A receptor gene ( ADORA 2 A ) modulates the psychological response to administration of the adenosine receptor antagonist caffeine .,
                    'spans': [([1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], '<<limited_variation>>'), ([8, 9, 10, 11, 12], '<<gene_or_protein>>'), ([15, 16, 17], '<<gene_or_protein>>'), ([21, 22, 23, 30], '<<pharmacodynamic_phenotype>>'), ([27, 28, 29], '<<chemical>>'), ([30], '<<chemical>>')],
                    'pred_spans': [([2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18], '<<limited_variation>>'), ([8, 9, 10, 11, 12], '<<gene_or_protein>>'), ([15, 16, 17], '<<gene_or_protein>>'), ([21, 22, 23, 24, 25, 26, 27, 28, 29, 30], '<<pharmacodynamic_phenotype>>'), ([27, 28, 29], '<<chemical>>'), ([30], '<<chemical>>')],
                    'entities' : ['1976 C > T polymorphism in the adenosine A 2 A receptor <<limited_variation>>', 'adenosine A 2 A receptor <<gene_or_protein>>', 'ADORA 2 A <<gene_or_protein>>', 'psychological response to caffeine <<pharmacodynamic_phenotype>>', 'adenosine receptor antagonist <<chemical>>', 'caffeine <<chemical>>'],
                    'pred_entities' : ['C > T polymorphism in the adenosine A 2 A receptor gene ( ADORA 2 A ) <<limited_variation>>', 'adenosine A 2 A receptor <<gene_or_protein>>', 'ADORA 2 A <<gene_or_protein>>', 'psychological response to administration of the adenosine receptor antagonist caffeine <<pharmacodynamic_phenotype>>', 'adenosine receptor antagonist <<chemical>>', 'caffeine <<chemical>>'] 

'sentence': These results suggest that AKR - 501 is an orally - active TPO receptor agonist that may be useful in the treatment of patients with thrombocytopenia .,
                    'spans': [([4, 5, 6], '<<chemical>>'), ([12], '<<chemical>>'), ([12, 13], '<<gene_or_protein>>'), ([25], '<<disease>>')],
                    'pred_spans': [([4, 5, 6], '<<chemical>>'), ([12, 13], '<<gene_or_protein>>'), ([12, 13, 14], '<<chemical>>'), ([25], '<<disease>>')],
                    'entities' : ['AKR - 501 <<chemical>>', 'TPO <<chemical>>', 'TPO receptor <<gene_or_protein>>', 'thrombocytopenia <<disease>>'],
                    'pred_entities' : ['AKR - 501 <<chemical>>', 'TPO receptor <<gene_or_protein>>', 'TPO receptor agonist <<chemical>>', 'thrombocytopenia <<disease>>'] 

'sentence': Toxic encephalopathy and delayed MTX clearance after high - dose methotrexate therapy in a child homozygous for the MTHFR C 677 T polymorphism .,
                    'spans': [([1], '<<disease>>'), ([4], '<<chemical>>'), ([4, 5], '<<pharmacokinetic_phenotype>>'), ([10], '<<chemical>>'), ([15, 16, 17, 18, 19, 20, 21, 22], '<<limited_variation>>'), ([18], '<<gene_or_protein>>')],
                    'pred_spans': [([0, 1], '<<disease>>'), ([3, 4, 5], '<<pharmacokinetic_phenotype>>'), ([4], '<<chemical>>'), ([10], '<<chemical>>'), ([18], '<<gene_or_protein>>'), ([18, 19, 20, 21, 22], '<<limited_variation>>')],
                    'entities' : ['encephalopathy <<disease>>', 'MTX <<chemical>>', 'MTX clearance <<pharmacokinetic_phenotype>>', 'methotrexate <<chemical>>', 'homozygous for the MTHFR C 677 T polymorphism <<limited_variation>>', 'MTHFR <<gene_or_protein>>'],
                    'pred_entities' : ['Toxic encephalopathy <<disease>>', 'delayed MTX clearance <<pharmacokinetic_phenotype>>', 'MTX <<chemical>>', 'methotrexate <<chemical>>', 'MTHFR <<gene_or_protein>>', 'MTHFR C 677 T polymorphism <<limited_variation>>'] 

'sentence': COMT inhibition by entacapone was higher in COMT ( HH ) than in COMT ( LL ) patients ( - 0 . 54 0 . 07 vs - 0 . 31 0 . 06 pmol / min / mg protein , p = 0 . 02 ) .,
                    'spans': [([0], '<<gene_or_protein>>'), ([0, 1, 2, 3], '<<pharmacodynamic_phenotype>>'), ([3], '<<chemical>>'), ([7], '<<gene_or_protein>>'), ([7, 8, 9, 10], '<<limited_variation>>'), ([13], '<<gene_or_protein>>'), ([13, 14, 15, 16], '<<limited_variation>>')],
                    'pred_spans': [([0], '<<gene_or_protein>>'), ([0, 1, 2, 3], '<<pharmacodynamic_phenotype>>'), ([3], '<<chemical>>'), ([7, 8, 9, 10], '<<limited_variation>>'), ([13], '<<gene_or_protein>>'), ([13, 14, 15, 16], '<<limited_variation>>')],
                    'entities' : ['COMT <<gene_or_protein>>', 'COMT inhibition by entacapone <<pharmacodynamic_phenotype>>', 'entacapone <<chemical>>', 'COMT <<gene_or_protein>>', 'COMT ( HH ) <<limited_variation>>', 'COMT <<gene_or_protein>>', 'COMT ( LL ) <<limited_variation>>'],
                    'pred_entities' : ['COMT <<gene_or_protein>>', 'COMT inhibition by entacapone <<pharmacodynamic_phenotype>>', 'entacapone <<chemical>>', 'COMT ( HH ) <<limited_variation>>', 'COMT <<gene_or_protein>>', 'COMT ( LL ) <<limited_variation>>'] 

'sentence': PATIENTS AND METHODS : Patients with HER 2 - positive locally advanced breast cancer or MBC were treated with 3 . 6 mg / kg T - DM 1 plus pertuzumab ( 840 - mg loading dose , then 420 mg subsequently ) once every 3 weeks .,
                    'spans': [([6, 7], '<<gene_or_protein>>'), ([6, 7, 8, 9], '<<phenotype>>'), ([6, 7, 8, 9, 12, 13], '<<disease>>'), ([6, 7, 8, 9, 15], '<<disease>>'), ([27, 28, 29, 30], '<<chemical>>')],
                    'pred_spans': [([6, 7], '<<gene_or_protein>>'), ([6, 7, 8, 9], '<<phenotype>>'), ([6, 7, 8, 9, 10, 11, 12, 13], '<<disease>>'), ([6, 7, 8, 9, 10, 11, 15], '<<disease>>'), ([25, 26, 27, 28], '<<chemical>>'), ([25, 26, 27, 28, 29, 30], '<<chemical>>'), ([30], '<<chemical>>')],
                    'entities' : ['HER 2 <<gene_or_protein>>', 'HER 2 - positive <<phenotype>>', 'HER 2 - positive breast cancer <<disease>>', 'HER 2 - positive MBC <<disease>>', 'DM 1 plus pertuzumab <<chemical>>'],
                    'pred_entities' : ['HER 2 <<gene_or_protein>>', 'HER 2 - positive <<phenotype>>', 'HER 2 - positive locally advanced breast cancer <<disease>>', 'HER 2 - positive locally advanced MBC <<disease>>', 'T - DM 1 <<chemical>>', 'T - DM 1 plus pertuzumab <<chemical>>', 'pertuzumab <<chemical>>'] 

'sentence': It was found that the EA extract of bitter gourd ( Momordica charantia ) , a common oriental vegetable , activated PPARalpha to an extent that was equivalent to or even higher than 10 microM Wy - 14643 , a known ligand of PPARalpha .,
                    'spans': [([5, 6, 7, 8, 9], '<<chemical>>'), ([21], '<<gene_or_protein>>'), ([35, 36, 37], '<<chemical>>'), ([43], '<<gene_or_protein>>')],
                    'pred_spans': [([5], '<<chemical>>'), ([8, 9], '<<chemical>>'), ([11, 12], '<<chemical>>'), ([21], '<<gene_or_protein>>'), ([35, 36, 37], '<<chemical>>'), ([43], '<<gene_or_protein>>')],
                    'entities' : ['EA extract of bitter gourd <<chemical>>', 'PPARalpha <<gene_or_protein>>', 'Wy - 14643 <<chemical>>', 'PPARalpha <<gene_or_protein>>'],
                    'pred_entities' : ['EA <<chemical>>', 'bitter gourd <<chemical>>', 'Momordica charantia <<chemical>>', 'PPARalpha <<gene_or_protein>>', 'Wy - 14643 <<chemical>>', 'PPARalpha <<gene_or_protein>>'] 

'sentence': This study used computer - assisted self - infusion of ethanol ( CASE ) to examine associations among OPRM 1 A 118 G genotype , subjective responses to alcohol and intravenous alcohol self - administration in young heavy drinkers ( n = 40 , mean age = 19 . 95 years , SD = 0 . 82 ) .,
                    'spans': [([10], '<<chemical>>'), ([18, 19], '<<gene_or_protein>>'), ([18, 19, 20, 21, 22], '<<limited_variation>>'), ([26, 27, 28], '<<pharmacodynamic_phenotype>>'), ([28], '<<chemical>>'), ([31], '<<chemical>>')],
                    'pred_spans': [([18, 19], '<<gene_or_protein>>'), ([18, 19, 20, 21, 22], '<<limited_variation>>'), ([25, 26, 27, 28], '<<pharmacodynamic_phenotype>>'), ([28], '<<chemical>>'), ([30, 31, 32, 33, 34], '<<phenotype>>'), ([37, 38], '<<phenotype>>')],
                    'entities' : ['ethanol <<chemical>>', 'OPRM 1 <<gene_or_protein>>', 'OPRM 1 A 118 G <<limited_variation>>', 'responses to alcohol <<pharmacodynamic_phenotype>>', 'alcohol <<chemical>>', 'alcohol <<chemical>>'],
                    'pred_entities' : ['OPRM 1 <<gene_or_protein>>', 'OPRM 1 A 118 G <<limited_variation>>', 'subjective responses to alcohol <<pharmacodynamic_phenotype>>', 'alcohol <<chemical>>', 'intravenous alcohol self - administration <<phenotype>>', 'heavy drinkers <<phenotype>>'] 

'sentence': GACI is linked to mutations in the ENPP 1 gene , which encodes for an enzyme that generates inorganic pyrophosphate ( PP ( i ) ) , a potent inhibitor of hydroxyapatite crystal formation .,
                    'spans': [([0], '<<disease>>'), ([4, 5, 6, 7, 8, 9], '<<limited_variation>>'), ([7, 8], '<<gene_or_protein>>'), ([18, 19], '<<chemical>>'), ([21, 22, 23, 24], '<<chemical>>'), ([31], '<<chemical>>')],
                    'pred_spans': [([0], '<<chemical>>'), ([4, 5, 6, 7, 8, 9], '<<limited_variation>>'), ([7, 8], '<<gene_or_protein>>'), ([18, 19], '<<chemical>>'), ([21, 22, 23, 24], '<<chemical>>'), ([31], '<<chemical>>'), ([31, 32, 33], '<<pharmacokinetic_phenotype>>')],
                    'entities' : ['GACI <<disease>>', 'mutations in the ENPP 1 gene <<limited_variation>>', 'ENPP 1 <<gene_or_protein>>', 'inorganic pyrophosphate <<chemical>>', 'PP ( i ) <<chemical>>', 'hydroxyapatite <<chemical>>'],
                    'pred_entities' : ['GACI <<chemical>>', 'mutations in the ENPP 1 gene <<limited_variation>>', 'ENPP 1 <<gene_or_protein>>', 'inorganic pyrophosphate <<chemical>>', 'PP ( i ) <<chemical>>', 'hydroxyapatite <<chemical>>', 'hydroxyapatite crystal formation <<pharmacokinetic_phenotype>>'] 

'sentence': The purpose of this study is to identify the cases where a probable hypersensitivity reaction to abacavir presented the HLA - B * 5701 allele .,
                    'spans': [([13, 14, 15, 16], '<<pharmacodynamic_phenotype>>'), ([16], '<<chemical>>'), ([19, 20, 21], '<<gene_or_protein>>'), ([19, 20, 21, 22, 23], '<<haplotype>>')],
                    'pred_spans': [([13, 14, 15, 16], '<<pharmacodynamic_phenotype>>'), ([16], '<<chemical>>'), ([19, 20, 21], '<<gene_or_protein>>'), ([19, 20, 21, 22, 23, 24], '<<limited_variation>>')],
                    'entities' : ['hypersensitivity reaction to abacavir <<pharmacodynamic_phenotype>>', 'abacavir <<chemical>>', 'HLA - B <<gene_or_protein>>', 'HLA - B * 5701 <<haplotype>>'],
                    'pred_entities' : ['hypersensitivity reaction to abacavir <<pharmacodynamic_phenotype>>', 'abacavir <<chemical>>', 'HLA - B <<gene_or_protein>>', 'HLA - B * 5701 allele <<limited_variation>>'] 

'sentence': Finally , DOR - 1 mutant mice do not develop analgesic tolerance to morphine , genetically demonstrating a central role for DOR - 1 in this process .,
                    'spans': [([2, 3, 4], '<<gene_or_protein>>'), ([2, 3, 4, 5], '<<limited_variation>>'), ([10, 11, 12, 13], '<<pharmacodynamic_phenotype>>'), ([13], '<<chemical>>'), ([21, 22, 23], '<<gene_or_protein>>')],
                    'pred_spans': [([2, 3, 4], '<<gene_or_protein>>'), ([2, 3, 4, 5], '<<limited_variation>>'), ([10, 11, 12, 13], '<<pharmacodynamic_phenotype>>'), ([13], '<<chemical>>'), ([21, 22, 23], '<<gene_or_protein>>')],
                    'entities' : ['DOR - 1 <<gene_or_protein>>', 'DOR - 1 mutant <<limited_variation>>', 'analgesic tolerance to morphine <<pharmacodynamic_phenotype>>', 'morphine <<chemical>>', 'DOR - 1 <<gene_or_protein>>'],
                    'pred_entities' : ['DOR - 1 <<gene_or_protein>>', 'DOR - 1 mutant <<limited_variation>>', 'analgesic tolerance to morphine <<pharmacodynamic_phenotype>>', 'morphine <<chemical>>', 'DOR - 1 <<gene_or_protein>>'] 

'sentence': We studied the consequences of VX - 770 interaction with CFTR incorporated in planar lipid bilayers and in proteoliposomes , using a novel flux - based assay .,
                    'spans': [([5, 6, 7], '<<chemical>>'), ([10], '<<gene_or_protein>>')],
                    'pred_spans': [([5, 6, 7], '<<chemical>>'), ([5, 6, 7, 8, 9, 10], '<<phenotype>>'), ([10], '<<gene_or_protein>>'), ([13, 14, 15], '<<pharmacokinetic_phenotype>>'), ([18], '<<gene_or_protein>>')],
                    'entities' : ['VX - 770 <<chemical>>', 'CFTR <<gene_or_protein>>'],
                    'pred_entities' : ['VX - 770 <<chemical>>', 'VX - 770 interaction with CFTR <<phenotype>>', 'CFTR <<gene_or_protein>>', 'planar lipid bilayers <<pharmacokinetic_phenotype>>', 'proteoliposomes <<gene_or_protein>>'] 

'sentence': The specificity of N Latex CDT for identifying alcohol abuse may be higher than for immunoassays that use column separation , because transferrin genetic variants do not interfere with measurements .,
                    'spans': [([5], '<<gene_or_protein>>'), ([8, 9], '<<disease>>'), ([22], '<<gene_or_protein>>'), ([22, 23, 24], '<<limited_variation>>')],
                    'pred_spans': [([3, 4, 5], '<<chemical>>'), ([8], '<<chemical>>'), ([8, 9], '<<disease>>'), ([22], '<<gene_or_protein>>'), ([22, 23, 24], '<<limited_variation>>')],
                    'entities' : ['CDT <<gene_or_protein>>', 'alcohol abuse <<disease>>', 'transferrin <<gene_or_protein>>', 'transferrin genetic variants <<limited_variation>>'],
                    'pred_entities' : ['N Latex CDT <<chemical>>', 'alcohol <<chemical>>', 'alcohol abuse <<disease>>', 'transferrin <<gene_or_protein>>', 'transferrin genetic variants <<limited_variation>>'] 

'sentence': We examined the role of Ranbp 2 haploinsufficiency on cellular and metabolic manifestations linked to tyrosine - hydroxylase ( TH ( + ) ) dopaminergic neurons and glial cells of the brain and retina upon acute challenge to 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) , a parkinsonian neurotoxin , which models facets of Parkinson disease .,
                    'spans': [([5, 6], '<<gene_or_protein>>'), ([5, 6, 7], '<<genomic_variation>>'), ([12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], '<<phenotype>>'), ([12, 13, 14, 27, 28, 29, 30, 31], '<<phenotype>>'), ([12, 13, 14, 33], '<<phenotype>>'), ([15, 16, 17], '<<gene_or_protein>>'), ([19, 20, 21, 22], '<<gene_or_protein>>'), ([38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54], '<<chemical>>'), ([56], '<<chemical>>'), ([60, 61], '<<chemical>>'), ([67, 68], '<<disease>>')],
                    'pred_spans': [([5, 6], '<<gene_or_protein>>'), ([5, 6, 7], '<<haplotype>>'), ([9, 12], '<<phenotype>>'), ([11, 12], '<<phenotype>>'), ([15, 16, 17], '<<gene_or_protein>>'), ([15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], '<<phenotype>>'), ([19, 20, 21, 22], '<<gene_or_protein>>'), ([35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57], '<<pharmacodynamic_phenotype>>'), ([56], '<<chemical>>'), ([60, 61], '<<chemical>>'), ([67, 68], '<<disease>>')],
                    'entities' : ['Ranbp 2 <<gene_or_protein>>', 'Ranbp 2 haploinsufficiency <<genomic_variation>>', 'manifestations linked to tyrosine - hydroxylase ( TH ( + ) ) dopaminergic neurons <<phenotype>>', 'manifestations linked to glial cells of the brain <<phenotype>>', 'manifestations linked to retina <<phenotype>>', 'tyrosine - hydroxylase <<gene_or_protein>>', 'TH ( + ) <<gene_or_protein>>', '1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine <<chemical>>', 'MPTP <<chemical>>', 'parkinsonian neurotoxin <<chemical>>', 'Parkinson disease <<disease>>'],
                    'pred_entities' : ['Ranbp 2 <<gene_or_protein>>', 'Ranbp 2 haploinsufficiency <<haplotype>>', 'cellular manifestations <<phenotype>>', 'metabolic manifestations <<phenotype>>', 'tyrosine - hydroxylase <<gene_or_protein>>', 'tyrosine - hydroxylase ( TH ( + ) ) dopaminergic neurons <<phenotype>>', 'TH ( + ) <<gene_or_protein>>', 'acute challenge to 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) <<pharmacodynamic_phenotype>>', 'MPTP <<chemical>>', 'parkinsonian neurotoxin <<chemical>>', 'Parkinson disease <<disease>>'] 

'sentence': We chose a 30 M concentration of 4 - HNE , which produced an approximately 50 % inhibition of complex I - or complex II - driven respiration , to assess whether prior in vivo Nrf 2 - ARE - activating compounds would increase the resistance of the isolated cortical mitochondria to 4 - HNE ' s mitotoxic effects .,
                    'spans': [([7, 8, 9], '<<chemical>>'), ([19, 20, 21, 26, 27], '<<genomic_factor>>'), ([23, 24, 25, 26, 27], '<<genomic_factor>>'), ([35, 36], '<<gene_or_protein>>'), ([35, 36, 37, 38], '<<genomic_factor>>'), ([35, 36, 37, 38, 39, 40, 41], '<<chemical>>'), ([45, 51, 52, 53, 54], '<<pharmacodynamic_phenotype>>'), ([52, 53, 54], '<<chemical>>')],
                    'pred_spans': [([7, 8, 9], '<<chemical>>'), ([19, 20, 21, 26, 27], '<<phenotype>>'), ([23, 24, 25, 26, 27], '<<phenotype>>'), ([35, 36, 37, 38], '<<gene_or_protein>>'), ([35, 36, 37, 38, 39, 40, 41], '<<chemical>>'), ([45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58], '<<pharmacodynamic_phenotype>>'), ([52, 53, 54], '<<chemical>>')],
                    'entities' : ['4 - HNE <<chemical>>', 'complex I - driven respiration <<genomic_factor>>', 'complex II - driven respiration <<genomic_factor>>', 'Nrf 2 <<gene_or_protein>>', 'Nrf 2 - ARE <<genomic_factor>>', 'Nrf 2 - ARE - activating compounds <<chemical>>', 'resistance to 4 - HNE <<pharmacodynamic_phenotype>>', '4 - HNE <<chemical>>'],
                    'pred_entities' : ['4 - HNE <<chemical>>', 'complex I - driven respiration <<phenotype>>', 'complex II - driven respiration <<phenotype>>', 'Nrf 2 - ARE <<gene_or_protein>>', 'Nrf 2 - ARE - activating compounds <<chemical>>', "resistance of the isolated cortical mitochondria to 4 - HNE ' s mitotoxic effects <<pharmacodynamic_phenotype>>", '4 - HNE <<chemical>>'] 

'sentence': CONCLUSIONS : Polymorphism of SLCO 1 B 1 c . 521 T > C could be a strong predictor of dose reduction of 6 - MP in maintenance chemotherapy in childhood ALL .,
                    'spans': [([4, 5, 6, 7], '<<gene_or_protein>>'), ([4, 5, 6, 7, 8, 9, 10, 11, 12, 13], '<<limited_variation>>'), ([20, 21, 22, 23, 24, 25], '<<pharmacodynamic_phenotype>>'), ([23, 24, 25], '<<chemical>>'), ([28], '<<chemical>>'), ([31], '<<disease>>')],
                    'pred_spans': [([2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], '<<limited_variation>>'), ([4, 5, 6, 7], '<<gene_or_protein>>'), ([20, 21, 22, 23, 24, 25], '<<pharmacodynamic_phenotype>>'), ([23, 24, 25], '<<chemical>>'), ([27, 28], '<<chemical>>'), ([31], '<<disease>>')],
                    'entities' : ['SLCO 1 B 1 <<gene_or_protein>>', 'SLCO 1 B 1 c . 521 T > C <<limited_variation>>', 'dose reduction of 6 - MP <<pharmacodynamic_phenotype>>', '6 - MP <<chemical>>', 'chemotherapy <<chemical>>', 'ALL <<disease>>'],
                    'pred_entities' : ['Polymorphism of SLCO 1 B 1 c . 521 T > C <<limited_variation>>', 'SLCO 1 B 1 <<gene_or_protein>>', 'dose reduction of 6 - MP <<pharmacodynamic_phenotype>>', '6 - MP <<chemical>>', 'maintenance chemotherapy <<chemical>>', 'ALL <<disease>>'] 

'sentence': CONCLUSIONS : We found no significant association between oxaliplatin - induced neuropathy and the GSTP 1 Ile ( 105 ) Val and AGXT Ile ( 340 ) Met polymorphisms .,
                    'spans': [([8], '<<chemical>>'), ([8, 9, 10, 11], '<<pharmacodynamic_phenotype>>'), ([11], '<<pharmacodynamic_phenotype>>'), ([14, 15], '<<gene_or_protein>>'), ([14, 15, 16, 17, 18, 19, 20], '<<limited_variation>>'), ([22], '<<gene_or_protein>>'), ([22, 23, 24, 25, 26, 27], '<<limited_variation>>')],
                    'pred_spans': [([8], '<<chemical>>'), ([8, 9, 10, 11], '<<pharmacodynamic_phenotype>>'), ([11], '<<pharmacodynamic_phenotype>>'), ([14, 15], '<<gene_or_protein>>'), ([14, 15, 16, 17, 18, 19, 20], '<<limited_variation>>'), ([22], '<<gene_or_protein>>'), ([22, 23, 24, 25, 26, 27], '<<limited_variation>>')],
                    'entities' : ['oxaliplatin <<chemical>>', 'oxaliplatin - induced neuropathy <<pharmacodynamic_phenotype>>', 'neuropathy <<pharmacodynamic_phenotype>>', 'GSTP 1 <<gene_or_protein>>', 'GSTP 1 Ile ( 105 ) Val <<limited_variation>>', 'AGXT <<gene_or_protein>>', 'AGXT Ile ( 340 ) Met <<limited_variation>>'],
                    'pred_entities' : ['oxaliplatin <<chemical>>', 'oxaliplatin - induced neuropathy <<pharmacodynamic_phenotype>>', 'neuropathy <<pharmacodynamic_phenotype>>', 'GSTP 1 <<gene_or_protein>>', 'GSTP 1 Ile ( 105 ) Val <<limited_variation>>', 'AGXT <<gene_or_protein>>', 'AGXT Ile ( 340 ) Met <<limited_variation>>'] 

'sentence': A positive control using 5 - azacytidine also reactivated p 16 INK 4 a .,
                    'spans': [([4, 5, 6], '<<chemical>>'), ([9, 10, 11, 12, 13], '<<gene_or_protein>>')],
                    'pred_spans': [([4, 5, 6], '<<chemical>>'), ([9, 10, 11, 12, 13], '<<gene_or_protein>>')],
                    'entities' : ['5 - azacytidine <<chemical>>', 'p 16 INK 4 a <<gene_or_protein>>'],
                    'pred_entities' : ['5 - azacytidine <<chemical>>', 'p 16 INK 4 a <<gene_or_protein>>'] 

'sentence': CONCLUSIONS : CYP 2 C 19 polymorphisms are frequent in Japanese , and the antiplatelet effect of clopidogrel is strongly affected by them in the real - world clinical setting .,
                    'spans': [([2, 3, 4, 5], '<<gene_or_protein>>'), ([2, 3, 4, 5, 6], '<<limited_variation>>'), ([14, 15, 16, 17], '<<pharmacodynamic_phenotype>>'), ([17], '<<chemical>>')],
                    'pred_spans': [([2, 3, 4, 5], '<<gene_or_protein>>'), ([2, 3, 4, 5, 6], '<<limited_variation>>'), ([14, 15, 16, 17], '<<pharmacodynamic_phenotype>>'), ([17], '<<chemical>>')],
                    'entities' : ['CYP 2 C 19 <<gene_or_protein>>', 'CYP 2 C 19 polymorphisms <<limited_variation>>', 'antiplatelet effect of clopidogrel <<pharmacodynamic_phenotype>>', 'clopidogrel <<chemical>>'],
                    'pred_entities' : ['CYP 2 C 19 <<gene_or_protein>>', 'CYP 2 C 19 polymorphisms <<limited_variation>>', 'antiplatelet effect of clopidogrel <<pharmacodynamic_phenotype>>', 'clopidogrel <<chemical>>'] 

'sentence': We examined the relation between spontaneous abortion and polymorphisms in two genes , glutathione S - transferase ( GSTM 1 ) and N - acetyltransferase ( NAT 2 ) , which are involved in the metabolism of xenobiotics .,
                    'spans': [([5, 6], '<<disease>>'), ([8, 9, 13, 14, 15, 16], '<<limited_variation>>'), ([8, 9, 22, 23, 24], '<<limited_variation>>'), ([13, 14, 15, 16], '<<gene_or_protein>>'), ([18, 19], '<<gene_or_protein>>'), ([22, 23, 24], '<<gene_or_protein>>'), ([26, 27], '<<gene_or_protein>>'), ([35, 36, 37], '<<pharmacokinetic_phenotype>>'), ([37], '<<chemical>>')],
                    'pred_spans': [([5, 6], '<<phenotype>>'), ([8, 9, 10, 11], '<<limited_variation>>'), ([13, 14, 15, 16], '<<gene_or_protein>>'), ([18, 19], '<<gene_or_protein>>'), ([22, 23, 24], '<<gene_or_protein>>'), ([26, 27], '<<gene_or_protein>>'), ([35, 36, 37], '<<pharmacokinetic_phenotype>>'), ([37], '<<chemical>>')],
                    'entities' : ['spontaneous abortion <<disease>>', 'polymorphisms in glutathione S - transferase <<limited_variation>>', 'polymorphisms in N - acetyltransferase <<limited_variation>>', 'glutathione S - transferase <<gene_or_protein>>', 'GSTM 1 <<gene_or_protein>>', 'N - acetyltransferase <<gene_or_protein>>', 'NAT 2 <<gene_or_protein>>', 'metabolism of xenobiotics <<pharmacokinetic_phenotype>>', 'xenobiotics <<chemical>>'],
                    'pred_entities' : ['spontaneous abortion <<phenotype>>', 'polymorphisms in two genes <<limited_variation>>', 'glutathione S - transferase <<gene_or_protein>>', 'GSTM 1 <<gene_or_protein>>', 'N - acetyltransferase <<gene_or_protein>>', 'NAT 2 <<gene_or_protein>>', 'metabolism of xenobiotics <<pharmacokinetic_phenotype>>', 'xenobiotics <<chemical>>'] 

'sentence': These surprising findings in a group of phenotypically similar patients with ER - positive , endocrine therapy - pretreated , HER 2 - negative metastases , are supported by preclinical data showing that sensitivity to 5 - fluorouracil is enhanced by deficiencies in chromatin remodeling and homologous recombination genes .,
                    'spans': [([11], '<<gene_or_protein>>'), ([11, 12, 13], '<<phenotype>>'), ([11, 12, 13, 24], '<<disease>>'), ([15, 16], '<<chemical>>'), ([20, 21], '<<gene_or_protein>>'), ([20, 21, 22, 23], '<<phenotype>>'), ([20, 21, 22, 23, 24], '<<disease>>'), ([33, 34, 35, 36, 37], '<<pharmacodynamic_phenotype>>'), ([35, 36, 37], '<<chemical>>'), ([41, 42, 43, 44], '<<genomic_factor>>'), ([46, 47, 48], '<<genomic_variation>>')],
                    'pred_spans': [([11], '<<gene_or_protein>>'), ([11, 12, 13], '<<phenotype>>'), ([15, 16], '<<chemical>>'), ([15, 16, 17, 18], '<<pharmacodynamic_phenotype>>'), ([20, 21], '<<gene_or_protein>>'), ([20, 21, 22, 23], '<<phenotype>>'), ([20, 21, 22, 23, 24], '<<disease>>'), ([33, 34, 35, 36, 37], '<<pharmacodynamic_phenotype>>'), ([35, 36, 37], '<<chemical>>'), ([41, 42, 43, 44, 48], '<<phenotype>>'), ([41, 42, 46, 47, 48], '<<phenotype>>'), ([43, 44], '<<gene_or_protein>>'), ([46, 47, 48], '<<gene_or_protein>>')],
                    'entities' : ['ER <<gene_or_protein>>', 'ER - positive <<phenotype>>', 'ER - positive metastases <<disease>>', 'endocrine therapy <<chemical>>', 'HER 2 <<gene_or_protein>>', 'HER 2 - negative <<phenotype>>', 'HER 2 - negative metastases <<disease>>', 'sensitivity to 5 - fluorouracil <<pharmacodynamic_phenotype>>', '5 - fluorouracil <<chemical>>', 'deficiencies in chromatin remodeling <<genomic_factor>>', 'homologous recombination genes <<genomic_variation>>'],
                    'pred_entities' : ['ER <<gene_or_protein>>', 'ER - positive <<phenotype>>', 'endocrine therapy <<chemical>>', 'endocrine therapy - pretreated <<pharmacodynamic_phenotype>>', 'HER 2 <<gene_or_protein>>', 'HER 2 - negative <<phenotype>>', 'HER 2 - negative metastases <<disease>>', 'sensitivity to 5 - fluorouracil <<pharmacodynamic_phenotype>>', '5 - fluorouracil <<chemical>>', 'deficiencies in chromatin remodeling genes <<phenotype>>', 'deficiencies in homologous recombination genes <<phenotype>>', 'chromatin remodeling <<gene_or_protein>>', 'homologous recombination genes <<gene_or_protein>>'] 

'sentence': DESIGN AND METHODS : We compared the clinical and hematologic responses to change in % V 617 F ( molecular response ) in 73 patients with polycythemia vera treated with either interferon ( rIFNa - 2 b : 28 , Peg - rIFNa - 2 a : 18 ) or non - interferon drugs ( n = 27 ) , which included hydroxyurea ( n = 8 ) , imatinib ( n = 12 ) , dasatinib ( n = 5 ) , busulfan ( n = 1 ) , and radioactive phosphorus ( n = 1 ) .,
                    'spans': [([7, 10], '<<pharmacodynamic_phenotype>>'), ([9, 10], '<<pharmacodynamic_phenotype>>'), ([15, 16, 17], '<<limited_variation>>'), ([26, 27], '<<disease>>'), ([31], '<<chemical>>'), ([33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47], '<<chemical>>'), ([50, 51, 52, 53], '<<chemical>>'), ([62], '<<chemical>>'), ([69], '<<chemical>>'), ([76], '<<chemical>>'), ([83], '<<chemical>>'), ([91, 92], '<<chemical>>')],
                    'pred_spans': [([7, 10], '<<pharmacodynamic_phenotype>>'), ([9, 10], '<<pharmacodynamic_phenotype>>'), ([12, 13, 14, 15, 16, 17], '<<phenotype>>'), ([14, 15, 16, 17], '<<phenotype>>'), ([19, 20], '<<pharmacodynamic_phenotype>>'), ([26, 27], '<<disease>>'), ([31], '<<chemical>>'), ([33, 34, 35, 36], '<<gene_or_protein>>'), ([33, 34, 35, 36, 37, 38], '<<chemical>>'), ([40, 41, 42, 43, 44, 45], '<<gene_or_protein>>'), ([40, 41, 42, 43, 44, 45, 46, 47], '<<chemical>>'), ([50, 51, 52], '<<chemical>>'), ([62], '<<chemical>>'), ([69], '<<chemical>>'), ([76], '<<chemical>>'), ([83], '<<chemical>>'), ([91, 92], '<<chemical>>')],
                    'entities' : ['clinical responses <<pharmacodynamic_phenotype>>', 'hematologic responses <<pharmacodynamic_phenotype>>', 'V 617 F <<limited_variation>>', 'polycythemia vera <<disease>>', 'interferon <<chemical>>', 'rIFNa - 2 b : 28 , Peg - rIFNa - 2 a : 18 <<chemical>>', 'non - interferon drugs <<chemical>>', 'hydroxyurea <<chemical>>', 'imatinib <<chemical>>', 'dasatinib <<chemical>>', 'busulfan <<chemical>>', 'radioactive phosphorus <<chemical>>'],
                    'pred_entities' : ['clinical responses <<pharmacodynamic_phenotype>>', 'hematologic responses <<pharmacodynamic_phenotype>>', 'change in % V 617 F <<phenotype>>', '% V 617 F <<phenotype>>', 'molecular response <<pharmacodynamic_phenotype>>', 'polycythemia vera <<disease>>', 'interferon <<chemical>>', 'rIFNa - 2 b <<gene_or_protein>>', 'rIFNa - 2 b : 28 <<chemical>>', 'Peg - rIFNa - 2 a <<gene_or_protein>>', 'Peg - rIFNa - 2 a : 18 <<chemical>>', 'non - interferon <<chemical>>', 'hydroxyurea <<chemical>>', 'imatinib <<chemical>>', 'dasatinib <<chemical>>', 'busulfan <<chemical>>', 'radioactive phosphorus <<chemical>>'] 

'sentence': Vemurafenib , a selective BRAF ( v - raf murine sarcoma viral oncogene homologue B 1 ) kinase inhibitor , is a new targeted biotherapy that improves survival in patients with metastatic melanomas harbouring the BRAF V 600 E mutation .,
                    'spans': [([0], '<<chemical>>'), ([4], '<<gene_or_protein>>'), ([4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18], '<<chemical>>'), ([6, 7, 8, 9, 10, 11, 12, 13, 14, 15], '<<gene_or_protein>>'), ([23, 24], '<<chemical>>'), ([27], '<<phenotype>>'), ([31, 32], '<<disease>>'), ([35], '<<gene_or_protein>>'), ([35, 36, 37, 38], '<<limited_variation>>')],
                    'pred_spans': [([0], '<<chemical>>'), ([4], '<<gene_or_protein>>'), ([4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18], '<<chemical>>'), ([9, 10], '<<disease>>'), ([11, 12, 13, 14, 15], '<<gene_or_protein>>'), ([17], '<<gene_or_protein>>'), ([27], '<<phenotype>>'), ([32], '<<disease>>'), ([35], '<<gene_or_protein>>'), ([35, 36, 37, 38, 39], '<<limited_variation>>')],
                    'entities' : ['Vemurafenib <<chemical>>', 'BRAF <<gene_or_protein>>', 'BRAF ( v - raf murine sarcoma viral oncogene homologue B 1 ) kinase inhibitor <<chemical>>', 'v - raf murine sarcoma viral oncogene homologue B 1 <<gene_or_protein>>', 'targeted biotherapy <<chemical>>', 'survival <<phenotype>>', 'metastatic melanomas <<disease>>', 'BRAF <<gene_or_protein>>', 'BRAF V 600 E <<limited_variation>>'],
                    'pred_entities' : ['Vemurafenib <<chemical>>', 'BRAF <<gene_or_protein>>', 'BRAF ( v - raf murine sarcoma viral oncogene homologue B 1 ) kinase inhibitor <<chemical>>', 'murine sarcoma <<disease>>', 'viral oncogene homologue B 1 <<gene_or_protein>>', 'kinase <<gene_or_protein>>', 'survival <<phenotype>>', 'melanomas <<disease>>', 'BRAF <<gene_or_protein>>', 'BRAF V 600 E mutation <<limited_variation>>'] 

'sentence': Following transient expression of MDR - 1 and MCJ , changes in the sensitivity of Sk - Ov - 3 cells to paclitaxel were detected whereas expression of Src , Bcl - 2 and Bcl - X ( L ) decreased the sensitivity of Sk - Ov - 3 cells to carboplatin .,
                    'spans': [([2, 3, 4, 5, 6], '<<phenotype>>'), ([2, 3, 8], '<<phenotype>>'), ([4, 5, 6], '<<gene_or_protein>>'), ([8], '<<gene_or_protein>>'), ([13, 14, 15, 16, 17, 18, 19, 20, 21, 22], '<<pharmacodynamic_phenotype>>'), ([22], '<<chemical>>'), ([26, 27, 28], '<<phenotype>>'), ([26, 27, 30, 31, 32], '<<phenotype>>'), ([26, 27, 34, 35, 36, 37, 38, 39], '<<phenotype>>'), ([28], '<<gene_or_protein>>'), ([30, 31, 32], '<<gene_or_protein>>'), ([34, 35, 36, 37, 38, 39], '<<gene_or_protein>>'), ([42, 43, 44, 45, 46, 47, 48, 49, 50, 51], '<<pharmacodynamic_phenotype>>'), ([51], '<<chemical>>')],
                    'pred_spans': [([2, 3, 4, 5, 6], '<<phenotype>>'), ([2, 3, 8], '<<phenotype>>'), ([4, 5, 6], '<<gene_or_protein>>'), ([8], '<<gene_or_protein>>'), ([13, 21, 22], '<<pharmacodynamic_phenotype>>'), ([13, 21, 51], '<<pharmacodynamic_phenotype>>'), ([22], '<<chemical>>'), ([26, 27, 28], '<<phenotype>>'), ([26, 27, 30, 31, 32], '<<phenotype>>'), ([26, 27, 34, 35, 36, 37, 38, 39], '<<phenotype>>'), ([28], '<<gene_or_protein>>'), ([30, 31, 32], '<<gene_or_protein>>'), ([34, 35, 36], '<<gene_or_protein>>'), ([42, 50, 51], '<<pharmacodynamic_phenotype>>'), ([51], '<<chemical>>')],
                    'entities' : ['expression of MDR - 1 <<phenotype>>', 'expression of MCJ <<phenotype>>', 'MDR - 1 <<gene_or_protein>>', 'MCJ <<gene_or_protein>>', 'sensitivity of Sk - Ov - 3 cells to paclitaxel <<pharmacodynamic_phenotype>>', 'paclitaxel <<chemical>>', 'expression of Src <<phenotype>>', 'expression of Bcl - 2 <<phenotype>>', 'expression of Bcl - X ( L ) <<phenotype>>', 'Src <<gene_or_protein>>', 'Bcl - 2 <<gene_or_protein>>', 'Bcl - X ( L ) <<gene_or_protein>>', 'sensitivity of Sk - Ov - 3 cells to carboplatin <<pharmacodynamic_phenotype>>', 'carboplatin <<chemical>>'],
                    'pred_entities' : ['expression of MDR - 1 <<phenotype>>', 'expression of MCJ <<phenotype>>', 'MDR - 1 <<gene_or_protein>>', 'MCJ <<gene_or_protein>>', 'sensitivity to paclitaxel <<pharmacodynamic_phenotype>>', 'sensitivity to carboplatin <<pharmacodynamic_phenotype>>', 'paclitaxel <<chemical>>', 'expression of Src <<phenotype>>', 'expression of Bcl - 2 <<phenotype>>', 'expression of Bcl - X ( L ) <<phenotype>>', 'Src <<gene_or_protein>>', 'Bcl - 2 <<gene_or_protein>>', 'Bcl - X <<gene_or_protein>>', 'sensitivity to carboplatin <<pharmacodynamic_phenotype>>', 'carboplatin <<chemical>>'] 

'sentence': Functionalized PEG - PEI copolymers complexed to exon - skipping oligonucleotides improve dystrophin expression in mdx mice .,
                    'spans': [([1], '<<chemical>>'), ([1, 2, 3, 4], '<<chemical>>'), ([3], '<<chemical>>'), ([12], '<<gene_or_protein>>'), ([12, 13], '<<phenotype>>')],
                    'pred_spans': [([1, 2, 3], '<<chemical>>'), ([1, 2, 3, 4], '<<chemical>>'), ([7, 8, 9, 10], '<<chemical>>'), ([12], '<<gene_or_protein>>'), ([12, 13], '<<phenotype>>')],
                    'entities' : ['PEG <<chemical>>', 'PEG - PEI copolymers <<chemical>>', 'PEI <<chemical>>', 'dystrophin <<gene_or_protein>>', 'dystrophin expression <<phenotype>>'],
                    'pred_entities' : ['PEG - PEI <<chemical>>', 'PEG - PEI copolymers <<chemical>>', 'exon - skipping oligonucleotides <<chemical>>', 'dystrophin <<gene_or_protein>>', 'dystrophin expression <<phenotype>>'] 

'sentence': Multiple linear regression analyses showed that the AC and CC CYP 7 A 1 genotypes accounted for 5 . 2 and 6 . 2 % of triglyceride concentration during follow - up and adjusted percent of change of triglyceride concentration , respectively .,
                    'spans': [([7, 10, 11, 12, 13, 14], '<<limited_variation>>'), ([9, 10, 11, 12, 13, 14], '<<limited_variation>>'), ([10, 11, 12, 13], '<<gene_or_protein>>'), ([26], '<<chemical>>'), ([26, 27], '<<pharmacodynamic_phenotype>>'), ([38], '<<chemical>>'), ([38, 39], '<<pharmacodynamic_phenotype>>')],
                    'pred_spans': [([7, 10, 11, 12, 13], '<<gene_or_protein>>'), ([7, 10, 11, 12, 13, 14], '<<limited_variation>>'), ([10, 11, 12, 13], '<<gene_or_protein>>'), ([26], '<<chemical>>'), ([26, 27], '<<pharmacodynamic_phenotype>>'), ([36, 37, 38, 39], '<<pharmacodynamic_phenotype>>'), ([38], '<<chemical>>')],
                    'entities' : ['AC CYP 7 A 1 genotypes <<limited_variation>>', 'CC CYP 7 A 1 genotypes <<limited_variation>>', 'CYP 7 A 1 <<gene_or_protein>>', 'triglyceride <<chemical>>', 'triglyceride concentration <<pharmacodynamic_phenotype>>', 'triglyceride <<chemical>>', 'triglyceride concentration <<pharmacodynamic_phenotype>>'],
                    'pred_entities' : ['AC CYP 7 A 1 <<gene_or_protein>>', 'AC CYP 7 A 1 genotypes <<limited_variation>>', 'CYP 7 A 1 <<gene_or_protein>>', 'triglyceride <<chemical>>', 'triglyceride concentration <<pharmacodynamic_phenotype>>', 'change of triglyceride concentration <<pharmacodynamic_phenotype>>', 'triglyceride <<chemical>>'] 

'sentence': A 2143 G was an important 23 S rRNA mutation associated with clarithromycin resistance and affected the H . pylori eradication efficacy .,
                    'spans': [([0, 1, 2], '<<limited_variation>>'), ([6, 7, 8], '<<genomic_factor>>'), ([6, 7, 8, 9], '<<limited_variation>>'), ([12], '<<chemical>>'), ([12, 13], '<<pharmacodynamic_phenotype>>'), ([17, 18, 19, 20, 21], '<<pharmacodynamic_phenotype>>')],
                    'pred_spans': [([0, 1, 2], '<<limited_variation>>'), ([6, 7, 8, 9], '<<limited_variation>>'), ([12], '<<chemical>>'), ([12, 13], '<<pharmacodynamic_phenotype>>'), ([17, 18, 19], '<<disease>>'), ([17, 18, 19, 20, 21], '<<pharmacodynamic_phenotype>>')],
                    'entities' : ['A 2143 G <<limited_variation>>', '23 S rRNA <<genomic_factor>>', '23 S rRNA mutation <<limited_variation>>', 'clarithromycin <<chemical>>', 'clarithromycin resistance <<pharmacodynamic_phenotype>>', 'H . pylori eradication efficacy <<pharmacodynamic_phenotype>>'],
                    'pred_entities' : ['A 2143 G <<limited_variation>>', '23 S rRNA mutation <<limited_variation>>', 'clarithromycin <<chemical>>', 'clarithromycin resistance <<pharmacodynamic_phenotype>>', 'H . pylori <<disease>>', 'H . pylori eradication efficacy <<pharmacodynamic_phenotype>>'] 

'sentence': The aim of this study was to evaluate the influence of CYP 3 A 5 polymorphism on the increase in CYP 3 A activity after living kidney transplantation , by measuring the plasma concentration of 4 b - hydroxycholesterol .,
                    'spans': [([11, 12, 13, 14], '<<gene_or_protein>>'), ([11, 12, 13, 14, 15], '<<limited_variation>>'), ([20, 21, 22], '<<gene_or_protein>>'), ([20, 21, 22, 23], '<<phenotype>>'), ([26, 27], '<<disease>>'), ([32, 33, 34, 35, 36, 37, 38], '<<pharmacodynamic_phenotype>>'), ([35, 36, 37, 38], '<<chemical>>')],
                    'pred_spans': [([11, 12, 13, 14], '<<gene_or_protein>>'), ([11, 12, 13, 14, 15], '<<limited_variation>>'), ([20, 21, 22], '<<gene_or_protein>>'), ([20, 21, 22, 23], '<<phenotype>>'), ([26, 27], '<<disease>>'), ([32, 33, 34, 35, 36, 37, 38], '<<pharmacodynamic_phenotype>>'), ([35, 36, 37, 38], '<<chemical>>')],
                    'entities' : ['CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 polymorphism <<limited_variation>>', 'CYP 3 A <<gene_or_protein>>', 'CYP 3 A activity <<phenotype>>', 'kidney transplantation <<disease>>', 'plasma concentration of 4 b - hydroxycholesterol <<pharmacodynamic_phenotype>>', '4 b - hydroxycholesterol <<chemical>>'],
                    'pred_entities' : ['CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 polymorphism <<limited_variation>>', 'CYP 3 A <<gene_or_protein>>', 'CYP 3 A activity <<phenotype>>', 'kidney transplantation <<disease>>', 'plasma concentration of 4 b - hydroxycholesterol <<pharmacodynamic_phenotype>>', '4 b - hydroxycholesterol <<chemical>>'] 

'sentence': Studies of aspirin , P 2 Y 12 inhibitors and other antiplatelet drugs clearly demonstrate how inhibition of platelet function increases bleeding risk .,
                    'spans': [([2], '<<chemical>>'), ([4, 5, 6, 7], '<<gene_or_protein>>'), ([4, 5, 6, 7, 8], '<<chemical>>'), ([11, 12], '<<chemical>>'), ([16, 17, 18, 19], '<<phenotype>>'), ([21], '<<disease>>')],
                    'pred_spans': [([2], '<<chemical>>'), ([4, 5, 6, 7], '<<gene_or_protein>>'), ([4, 5, 6, 7, 8], '<<chemical>>'), ([11, 12], '<<chemical>>'), ([16, 17, 18, 19], '<<phenotype>>'), ([18, 19], '<<phenotype>>'), ([21], '<<disease>>')],
                    'entities' : ['aspirin <<chemical>>', 'P 2 Y 12 <<gene_or_protein>>', 'P 2 Y 12 inhibitors <<chemical>>', 'antiplatelet drugs <<chemical>>', 'inhibition of platelet function <<phenotype>>', 'bleeding <<disease>>'],
                    'pred_entities' : ['aspirin <<chemical>>', 'P 2 Y 12 <<gene_or_protein>>', 'P 2 Y 12 inhibitors <<chemical>>', 'antiplatelet drugs <<chemical>>', 'inhibition of platelet function <<phenotype>>', 'platelet function <<phenotype>>', 'bleeding <<disease>>'] 

'sentence': When stratified by the COMT high activity haplotype , a beneficial effect of propranolol on pain perception was noted in patients not carrying this haplotype , a diminished benefit was observed in the heterozygotes , and no benefit was noted in the homozygotes .,
                    'spans': [([4], '<<gene_or_protein>>'), ([4, 5, 6, 7], '<<haplotype>>'), ([11, 12, 13, 14, 15, 16], '<<pharmacodynamic_phenotype>>'), ([13], '<<chemical>>'), ([15, 16], '<<phenotype>>'), ([24], '<<haplotype>>'), ([33], '<<limited_variation>>'), ([42], '<<limited_variation>>')],
                    'pred_spans': [([4], '<<gene_or_protein>>'), ([4, 5, 6, 7], '<<haplotype>>'), ([10, 11, 12, 13], '<<pharmacodynamic_phenotype>>'), ([13], '<<chemical>>'), ([15, 16], '<<pharmacodynamic_phenotype>>'), ([24], '<<haplotype>>'), ([28], '<<pharmacodynamic_phenotype>>'), ([33], '<<limited_variation>>'), ([42], '<<limited_variation>>')],
                    'entities' : ['COMT <<gene_or_protein>>', 'COMT high activity haplotype <<haplotype>>', 'effect of propranolol on pain perception <<pharmacodynamic_phenotype>>', 'propranolol <<chemical>>', 'pain perception <<phenotype>>', 'haplotype <<haplotype>>', 'heterozygotes <<limited_variation>>', 'homozygotes <<limited_variation>>'],
                    'pred_entities' : ['COMT <<gene_or_protein>>', 'COMT high activity haplotype <<haplotype>>', 'beneficial effect of propranolol <<pharmacodynamic_phenotype>>', 'propranolol <<chemical>>', 'pain perception <<pharmacodynamic_phenotype>>', 'haplotype <<haplotype>>', 'benefit <<pharmacodynamic_phenotype>>', 'heterozygotes <<limited_variation>>', 'homozygotes <<limited_variation>>'] 

'sentence': We showed that mutation of one of the two N - linked GP 2 glycosylation sites was highly detrimental to the antigenicity and immunogenicity of GP .,
                    'spans': [([3, 4, 9, 10, 11, 12, 13, 14, 15], '<<limited_variation>>'), ([12, 13], '<<gene_or_protein>>'), ([12, 13, 14, 15], '<<genomic_factor>>'), ([21, 24, 25], '<<phenotype>>'), ([23, 24, 25], '<<phenotype>>'), ([25], '<<gene_or_protein>>')],
                    'pred_spans': [([3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], '<<limited_variation>>'), ([12, 13], '<<gene_or_protein>>'), ([21, 24, 25], '<<pharmacodynamic_phenotype>>'), ([23, 24, 25], '<<pharmacodynamic_phenotype>>'), ([25], '<<chemical>>')],
                    'entities' : ['mutation of N - linked GP 2 glycosylation sites <<limited_variation>>', 'GP 2 <<gene_or_protein>>', 'GP 2 glycosylation sites <<genomic_factor>>', 'antigenicity of GP <<phenotype>>', 'immunogenicity of GP <<phenotype>>', 'GP <<gene_or_protein>>'],
                    'pred_entities' : ['mutation of one of the two N - linked GP 2 glycosylation sites <<limited_variation>>', 'GP 2 <<gene_or_protein>>', 'antigenicity of GP <<pharmacodynamic_phenotype>>', 'immunogenicity of GP <<pharmacodynamic_phenotype>>', 'GP <<chemical>>'] 

'sentence': RESULTS : Neither the mean AUC ( 0 - infinity ) ( geometric mean ratio : 1 . 01 ; 95 % CI : 0 . 93 - 1 . 1 , P = 0 . 88 ) nor the mean C ( max ) ( geometric mean ratio : 1 . 05 ; 95 % CI : 0 . 94 - 1 . 2 , P = 0 . 35 ) of repaglinide were statistically significantly different in the group carrying the CYP 2 C 8 * 3 mutant allele compared with wild - types .,
                    'spans': [([4, 5, 73], '<<pharmacokinetic_phenotype>>'), ([40, 41, 42, 43, 44, 73], '<<pharmacodynamic_phenotype>>'), ([73], '<<chemical>>'), ([83, 84, 85, 86], '<<gene_or_protein>>'), ([83, 84, 85, 86, 87, 88, 89], '<<haplotype>>'), ([93, 94, 95], '<<haplotype>>')],
                    'pred_spans': [([5, 6, 7, 8, 9, 10], '<<pharmacokinetic_phenotype>>'), ([41, 42, 43, 44], '<<phenotype>>'), ([73], '<<chemical>>'), ([83, 84, 85, 86], '<<gene_or_protein>>'), ([83, 84, 85, 86, 87, 88], '<<haplotype>>'), ([93, 94, 95], '<<limited_variation>>')],
                    'entities' : ['mean AUC repaglinide <<pharmacokinetic_phenotype>>', 'mean C ( max ) repaglinide <<pharmacodynamic_phenotype>>', 'repaglinide <<chemical>>', 'CYP 2 C 8 <<gene_or_protein>>', 'CYP 2 C 8 * 3 mutant <<haplotype>>', 'wild - types <<haplotype>>'],
                    'pred_entities' : ['AUC ( 0 - infinity ) <<pharmacokinetic_phenotype>>', 'C ( max ) <<phenotype>>', 'repaglinide <<chemical>>', 'CYP 2 C 8 <<gene_or_protein>>', 'CYP 2 C 8 * 3 <<haplotype>>', 'wild - types <<limited_variation>>'] 

'sentence': Association of gene polymorphisms encoding dopaminergic system components and platelet MAO - B activity with alcohol dependence and alcohol dependence - related phenotypes .,
                    'spans': [([2, 3, 4, 5, 6, 7], '<<limited_variation>>'), ([5, 6, 7], '<<gene_or_protein>>'), ([10, 11, 12], '<<gene_or_protein>>'), ([10, 11, 12, 13], '<<phenotype>>'), ([15], '<<chemical>>'), ([15, 16], '<<disease>>'), ([18], '<<chemical>>'), ([18, 19], '<<disease>>'), ([18, 19, 20, 21, 22], '<<phenotype>>')],
                    'pred_spans': [([2, 3, 4, 5, 6, 7], '<<limited_variation>>'), ([2, 3, 4, 9, 10, 11, 12, 13], '<<limited_variation>>'), ([5, 6, 7], '<<gene_or_protein>>'), ([9, 10, 11, 12, 13], '<<phenotype>>'), ([10, 11, 12], '<<gene_or_protein>>'), ([15], '<<chemical>>'), ([15, 16], '<<disease>>'), ([18, 19, 20, 21, 22], '<<phenotype>>')],
                    'entities' : ['gene polymorphisms encoding dopaminergic system components <<limited_variation>>', 'dopaminergic system components <<gene_or_protein>>', 'MAO - B <<gene_or_protein>>', 'MAO - B activity <<phenotype>>', 'alcohol <<chemical>>', 'alcohol dependence <<disease>>', 'alcohol <<chemical>>', 'alcohol dependence <<disease>>', 'alcohol dependence - related phenotypes <<phenotype>>'],
                    'pred_entities' : ['gene polymorphisms encoding dopaminergic system components <<limited_variation>>', 'gene polymorphisms encoding platelet MAO - B activity <<limited_variation>>', 'dopaminergic system components <<gene_or_protein>>', 'platelet MAO - B activity <<phenotype>>', 'MAO - B <<gene_or_protein>>', 'alcohol <<chemical>>', 'alcohol dependence <<disease>>', 'alcohol dependence - related phenotypes <<phenotype>>'] 

'sentence': We demonstrate that KIT exon 8 mutations result in constitutive ligand - independent kinase activation that can be inhibited by clinically relevant concentrations of imatinib .,
                    'spans': [([3], '<<gene_or_protein>>'), ([3, 4, 5], '<<genomic_factor>>'), ([3, 4, 5, 6], '<<limited_variation>>'), ([13], '<<gene_or_protein>>'), ([13, 14], '<<phenotype>>'), ([22, 23, 24], '<<pharmacodynamic_phenotype>>'), ([24], '<<chemical>>')],
                    'pred_spans': [([3], '<<gene_or_protein>>'), ([3, 4, 5], '<<genomic_factor>>'), ([3, 4, 5, 6], '<<limited_variation>>'), ([9, 10, 11, 12, 13, 14], '<<phenotype>>'), ([10, 11, 12, 13], '<<gene_or_protein>>'), ([24], '<<chemical>>')],
                    'entities' : ['KIT <<gene_or_protein>>', 'KIT exon 8 <<genomic_factor>>', 'KIT exon 8 mutations <<limited_variation>>', 'kinase <<gene_or_protein>>', 'kinase activation <<phenotype>>', 'concentrations of imatinib <<pharmacodynamic_phenotype>>', 'imatinib <<chemical>>'],
                    'pred_entities' : ['KIT <<gene_or_protein>>', 'KIT exon 8 <<genomic_factor>>', 'KIT exon 8 mutations <<limited_variation>>', 'constitutive ligand - independent kinase activation <<phenotype>>', 'ligand - independent kinase <<gene_or_protein>>', 'imatinib <<chemical>>'] 

'sentence': Studies on the eukaryotic enzymes by NMR and crystallography have facilitated understanding substrate specificities of human NAT 1 ( 5 - aminosalicylate and p - aminobenzoic acid ) and human NAT 2 ( sulphamethazine ) .,
                    'spans': [([12, 13, 14, 15, 16, 17], '<<chemical>>'), ([12, 13, 14, 29, 30, 31], '<<chemical>>'), ([16, 17], '<<gene_or_protein>>'), ([19, 20, 21], '<<chemical>>'), ([23, 24, 25, 26], '<<chemical>>'), ([30, 31], '<<gene_or_protein>>'), ([33], '<<chemical>>')],
                    'pred_spans': [([3, 4], '<<gene_or_protein>>'), ([16, 17], '<<gene_or_protein>>'), ([19, 20, 21], '<<chemical>>'), ([23, 24, 25, 26], '<<chemical>>'), ([30, 31], '<<gene_or_protein>>'), ([33], '<<chemical>>')],
                    'entities' : ['substrate specificities of human NAT 1 <<chemical>>', 'substrate specificities of human NAT 2 <<chemical>>', 'NAT 1 <<gene_or_protein>>', '5 - aminosalicylate <<chemical>>', 'p - aminobenzoic acid <<chemical>>', 'NAT 2 <<gene_or_protein>>', 'sulphamethazine <<chemical>>'],
                    'pred_entities' : ['eukaryotic enzymes <<gene_or_protein>>', 'NAT 1 <<gene_or_protein>>', '5 - aminosalicylate <<chemical>>', 'p - aminobenzoic acid <<chemical>>', 'NAT 2 <<gene_or_protein>>', 'sulphamethazine <<chemical>>'] 

'sentence': MAIN OUTCOME MEASURES : Gene variants of dopamine system components ( the dopamine transporter variable nucleotide tandem repeat , D 2 receptor Taq A 1 / A 2 , D 4 receptor variable nucleotide tandem repeat , and catechol - O - methyltransferase Val 158 Met polymorphisms ) and change in [ 11 C ] raclopride binding potential in the ventral caudate / nucleus accumbens on positron emission tomography scans .,
                    'spans': [([4, 5, 6, 7, 8, 9], '<<genomic_variation>>'), ([12, 13], '<<gene_or_protein>>'), ([12, 13, 14, 15, 16, 17], '<<genomic_variation>>'), ([19, 20, 21, 22], '<<gene_or_protein>>'), ([19, 20, 21, 22, 23, 24, 25, 26, 27], '<<limited_variation>>'), ([29, 30, 31], '<<gene_or_protein>>'), ([29, 30, 31, 32, 33, 34, 35], '<<genomic_variation>>'), ([38, 39, 40, 41, 42], '<<gene_or_protein>>'), ([38, 39, 40, 41, 42, 43, 44, 45, 46], '<<limited_variation>>'), ([55], '<<chemical>>'), ([55, 56, 57], '<<phenotype>>')],
                    'pred_spans': [([5, 6, 7, 8, 9], '<<limited_variation>>'), ([7, 13], '<<gene_or_protein>>'), ([12, 13, 14, 15, 16, 17], '<<limited_variation>>'), ([19, 20, 21], '<<gene_or_protein>>'), ([19, 20, 21, 22, 23, 24, 25, 26, 27, 46], '<<limited_variation>>'), ([29, 30, 31], '<<gene_or_protein>>'), ([29, 30, 31, 32, 33, 34, 35], '<<limited_variation>>'), ([38, 39, 40, 41, 42], '<<gene_or_protein>>'), ([38, 39, 40, 41, 42, 43, 44, 45, 46], '<<limited_variation>>'), ([51, 52, 53, 54, 55, 56, 57], '<<pharmacokinetic_phenotype>>'), ([55], '<<chemical>>')],
                    'entities' : ['Gene variants of dopamine system components <<genomic_variation>>', 'dopamine transporter <<gene_or_protein>>', 'dopamine transporter variable nucleotide tandem repeat <<genomic_variation>>', 'D 2 receptor Taq <<gene_or_protein>>', 'D 2 receptor Taq A 1 / A 2 <<limited_variation>>', 'D 4 receptor <<gene_or_protein>>', 'D 4 receptor variable nucleotide tandem repeat <<genomic_variation>>', 'catechol - O - methyltransferase <<gene_or_protein>>', 'catechol - O - methyltransferase Val 158 Met polymorphisms <<limited_variation>>', 'raclopride <<chemical>>', 'raclopride binding potential <<phenotype>>'],
                    'pred_entities' : ['variants of dopamine system components <<limited_variation>>', 'dopamine transporter <<gene_or_protein>>', 'dopamine transporter variable nucleotide tandem repeat <<limited_variation>>', 'D 2 receptor <<gene_or_protein>>', 'D 2 receptor Taq A 1 / A 2 polymorphisms <<limited_variation>>', 'D 4 receptor <<gene_or_protein>>', 'D 4 receptor variable nucleotide tandem repeat <<limited_variation>>', 'catechol - O - methyltransferase <<gene_or_protein>>', 'catechol - O - methyltransferase Val 158 Met polymorphisms <<limited_variation>>', '[ 11 C ] raclopride binding potential <<pharmacokinetic_phenotype>>', 'raclopride <<chemical>>'] 

'sentence': CONCLUSIONS : Our study shows that increased serum level of PTH and decreased fetuin - A and vitamin D levels may increase susceptibility of atherosclerosis in patients with hemodialysis through VDR gene FokI and ApaI polymorphisms .,
                    'spans': [([7, 8, 9, 10], '<<phenotype>>'), ([10], '<<gene_or_protein>>'), ([13, 14, 15], '<<gene_or_protein>>'), ([13, 14, 15, 19], '<<phenotype>>'), ([17, 18], '<<chemical>>'), ([17, 18, 19], '<<pharmacodynamic_phenotype>>'), ([24], '<<disease>>'), ([30], '<<gene_or_protein>>'), ([30, 31, 32, 35], '<<limited_variation>>'), ([30, 31, 34, 35], '<<limited_variation>>')],
                    'pred_spans': [([7, 8, 9, 10], '<<pharmacodynamic_phenotype>>'), ([10], '<<chemical>>'), ([12, 13, 14, 15, 16, 17, 18, 19], '<<pharmacodynamic_phenotype>>'), ([13, 14, 15], '<<gene_or_protein>>'), ([13, 14, 15, 16, 17, 18], '<<chemical>>'), ([17, 18], '<<chemical>>'), ([22, 23, 24], '<<pharmacodynamic_phenotype>>'), ([24], '<<disease>>'), ([28], '<<disease>>'), ([30], '<<gene_or_protein>>'), ([30, 31, 32, 35], '<<limited_variation>>'), ([30, 31, 34, 35], '<<limited_variation>>')],
                    'entities' : ['serum level of PTH <<phenotype>>', 'PTH <<gene_or_protein>>', 'fetuin - A <<gene_or_protein>>', 'fetuin - A levels <<phenotype>>', 'vitamin D <<chemical>>', 'vitamin D levels <<pharmacodynamic_phenotype>>', 'atherosclerosis <<disease>>', 'VDR <<gene_or_protein>>', 'VDR gene FokI polymorphisms <<limited_variation>>', 'VDR gene ApaI polymorphisms <<limited_variation>>'],
                    'pred_entities' : ['serum level of PTH <<pharmacodynamic_phenotype>>', 'PTH <<chemical>>', 'decreased fetuin - A and vitamin D levels <<pharmacodynamic_phenotype>>', 'fetuin - A <<gene_or_protein>>', 'fetuin - A and vitamin D <<chemical>>', 'vitamin D <<chemical>>', 'susceptibility of atherosclerosis <<pharmacodynamic_phenotype>>', 'atherosclerosis <<disease>>', 'hemodialysis <<disease>>', 'VDR <<gene_or_protein>>', 'VDR gene FokI polymorphisms <<limited_variation>>', 'VDR gene ApaI polymorphisms <<limited_variation>>'] 

'sentence': Epidermal growth factor receptor gene copy number , K - ras mutation and pathological response to preoperative cetuximab , 5 - FU and radiation therapy in locally advanced rectal cancer .,
                    'spans': [([0, 1, 2, 3], '<<gene_or_protein>>'), ([0, 1, 2, 3, 4, 5, 6], '<<genomic_variation>>'), ([8, 9, 10], '<<gene_or_protein>>'), ([8, 9, 10, 11], '<<limited_variation>>'), ([13, 14, 15, 16, 17], '<<pharmacodynamic_phenotype>>'), ([13, 14, 15, 16, 19, 20, 21], '<<pharmacodynamic_phenotype>>'), ([13, 14, 15, 16, 23, 24], '<<pharmacodynamic_phenotype>>'), ([17], '<<chemical>>'), ([19, 20, 21], '<<chemical>>'), ([23, 24], '<<chemical>>'), ([28, 29], '<<disease>>')],
                    'pred_spans': [([0, 1, 2, 3], '<<gene_or_protein>>'), ([0, 1, 2, 3, 4, 5, 6], '<<limited_variation>>'), ([8, 9, 10], '<<gene_or_protein>>'), ([8, 9, 10, 11], '<<limited_variation>>'), ([13, 14, 15, 16, 17], '<<pharmacodynamic_phenotype>>'), ([13, 14, 15, 19, 20, 21], '<<pharmacodynamic_phenotype>>'), ([17], '<<chemical>>'), ([19, 20, 21], '<<chemical>>'), ([23], '<<chemical>>'), ([28, 29], '<<disease>>')],
                    'entities' : ['Epidermal growth factor receptor <<gene_or_protein>>', 'Epidermal growth factor receptor gene copy number <<genomic_variation>>', 'K - ras <<gene_or_protein>>', 'K - ras mutation <<limited_variation>>', 'pathological response to preoperative cetuximab <<pharmacodynamic_phenotype>>', 'pathological response to preoperative 5 - FU <<pharmacodynamic_phenotype>>', 'pathological response to preoperative radiation therapy <<pharmacodynamic_phenotype>>', 'cetuximab <<chemical>>', '5 - FU <<chemical>>', 'radiation therapy <<chemical>>', 'rectal cancer <<disease>>'],
                    'pred_entities' : ['Epidermal growth factor receptor <<gene_or_protein>>', 'Epidermal growth factor receptor gene copy number <<limited_variation>>', 'K - ras <<gene_or_protein>>', 'K - ras mutation <<limited_variation>>', 'pathological response to preoperative cetuximab <<pharmacodynamic_phenotype>>', 'pathological response to 5 - FU <<pharmacodynamic_phenotype>>', 'cetuximab <<chemical>>', '5 - FU <<chemical>>', 'radiation <<chemical>>', 'rectal cancer <<disease>>'] 

'sentence': In postmenopausal women who were using combined estrogen - progestin therapy ( EPT ) at cohort enrollment , the OR of breast cancer was 2 . 31 ( 95 % CI = 1 . 47 - 3 . 62 ) per minor allele of rs 4149013 in SLCO 1 B 1 ( P = 0 . 0003 ; within - gene PACT = 0 . 002 ; overall PACT = 0 . 023 ) .,
                    'spans': [([6, 7, 8, 9, 10], '<<chemical>>'), ([7], '<<chemical>>'), ([9], '<<chemical>>'), ([12], '<<chemical>>'), ([19], '<<phenotype>>'), ([21, 22], '<<disease>>'), ([44, 45], '<<limited_variation>>'), ([47, 48, 49, 50], '<<gene_or_protein>>')],
                    'pred_spans': [([6, 7, 8, 9, 10], '<<chemical>>'), ([7], '<<chemical>>'), ([9], '<<chemical>>'), ([12], '<<chemical>>'), ([21, 22], '<<disease>>'), ([44, 45], '<<limited_variation>>'), ([47, 48, 49, 50], '<<gene_or_protein>>')],
                    'entities' : ['combined estrogen - progestin therapy <<chemical>>', 'estrogen <<chemical>>', 'progestin <<chemical>>', 'EPT <<chemical>>', 'OR <<phenotype>>', 'breast cancer <<disease>>', 'rs 4149013 <<limited_variation>>', 'SLCO 1 B 1 <<gene_or_protein>>'],
                    'pred_entities' : ['combined estrogen - progestin therapy <<chemical>>', 'estrogen <<chemical>>', 'progestin <<chemical>>', 'EPT <<chemical>>', 'breast cancer <<disease>>', 'rs 4149013 <<limited_variation>>', 'SLCO 1 B 1 <<gene_or_protein>>'] 

'sentence': CONCLUSION : Determination of the CYP 3 A 5 genotype would be helpful in the design of adequate immunosuppressive treatment and in lowering toxicity by predicting the doses of tacrolimus required for the induction and maintenance phases in individual kidney transplant recipients .,
                    'spans': [([5, 6, 7, 8], '<<gene_or_protein>>'), ([5, 6, 7, 8, 9], '<<limited_variation>>'), ([18, 19], '<<chemical>>'), ([23], '<<pharmacodynamic_phenotype>>'), ([27, 28, 29, 30], '<<pharmacodynamic_phenotype>>'), ([29], '<<chemical>>'), ([39, 40], '<<disease>>')],
                    'pred_spans': [([5, 6, 7, 8], '<<gene_or_protein>>'), ([5, 6, 7, 8, 9], '<<limited_variation>>'), ([18, 19], '<<chemical>>'), ([23], '<<pharmacodynamic_phenotype>>'), ([29], '<<chemical>>'), ([39, 40], '<<disease>>')],
                    'entities' : ['CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 genotype <<limited_variation>>', 'immunosuppressive treatment <<chemical>>', 'toxicity <<pharmacodynamic_phenotype>>', 'doses of tacrolimus required <<pharmacodynamic_phenotype>>', 'tacrolimus <<chemical>>', 'kidney transplant <<disease>>'],
                    'pred_entities' : ['CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 genotype <<limited_variation>>', 'immunosuppressive treatment <<chemical>>', 'toxicity <<pharmacodynamic_phenotype>>', 'tacrolimus <<chemical>>', 'kidney transplant <<disease>>'] 

'sentence': Association of HLA - B * 5701 genotypes and abacavir - induced hypersensitivity reaction : a systematic review and meta - analysis .,
                    'spans': [([2, 3, 4], '<<gene_or_protein>>'), ([2, 3, 4, 5, 6], '<<haplotype>>'), ([9], '<<chemical>>'), ([9, 10, 11, 12, 13], '<<pharmacodynamic_phenotype>>'), ([12, 13], '<<pharmacodynamic_phenotype>>')],
                    'pred_spans': [([2, 3, 4], '<<gene_or_protein>>'), ([2, 3, 4, 5, 6], '<<haplotype>>'), ([9], '<<chemical>>'), ([9, 10, 11, 12, 13], '<<pharmacodynamic_phenotype>>'), ([12, 13], '<<pharmacodynamic_phenotype>>')],
                    'entities' : ['HLA - B <<gene_or_protein>>', 'HLA - B * 5701 <<haplotype>>', 'abacavir <<chemical>>', 'abacavir - induced hypersensitivity reaction <<pharmacodynamic_phenotype>>', 'hypersensitivity reaction <<pharmacodynamic_phenotype>>'],
                    'pred_entities' : ['HLA - B <<gene_or_protein>>', 'HLA - B * 5701 <<haplotype>>', 'abacavir <<chemical>>', 'abacavir - induced hypersensitivity reaction <<pharmacodynamic_phenotype>>', 'hypersensitivity reaction <<pharmacodynamic_phenotype>>'] 

'sentence': This combination of R and L genotypes was associated with lower PON 1 activity towards diazoxon in both cases and controls .,
                    'spans': [([1, 2, 3, 4, 5, 6], '<<limited_variation>>'), ([3], '<<limited_variation>>'), ([5], '<<limited_variation>>'), ([11, 12], '<<gene_or_protein>>'), ([11, 12, 13], '<<pharmacokinetic_phenotype>>'), ([11, 12, 13, 14, 15], '<<pharmacokinetic_phenotype>>'), ([15], '<<chemical>>')],
                    'pred_spans': [([3, 6], '<<limited_variation>>'), ([5, 6], '<<limited_variation>>'), ([11, 12], '<<gene_or_protein>>'), ([11, 12, 13, 14, 15], '<<phenotype>>'), ([15], '<<chemical>>')],
                    'entities' : ['combination of R and L genotypes <<limited_variation>>', 'R <<limited_variation>>', 'L <<limited_variation>>', 'PON 1 <<gene_or_protein>>', 'PON 1 activity <<pharmacokinetic_phenotype>>', 'PON 1 activity towards diazoxon <<pharmacokinetic_phenotype>>', 'diazoxon <<chemical>>'],
                    'pred_entities' : ['R genotypes <<limited_variation>>', 'L genotypes <<limited_variation>>', 'PON 1 <<gene_or_protein>>', 'PON 1 activity towards diazoxon <<phenotype>>', 'diazoxon <<chemical>>'] 

'sentence': Phenytoin appears to increase LPV clearance via CYP 3 A 4 induction , which is not offset by the presence of low - dose RTV .,
                    'spans': [([0], '<<chemical>>'), ([4], '<<chemical>>'), ([4, 5], '<<pharmacokinetic_phenotype>>'), ([7, 8, 9, 10], '<<gene_or_protein>>'), ([7, 8, 9, 10, 11], '<<phenotype>>'), ([24], '<<chemical>>')],
                    'pred_spans': [([0], '<<chemical>>'), ([4], '<<chemical>>'), ([4, 5], '<<pharmacokinetic_phenotype>>'), ([7, 8, 9, 10], '<<gene_or_protein>>'), ([24], '<<chemical>>')],
                    'entities' : ['Phenytoin <<chemical>>', 'LPV <<chemical>>', 'LPV clearance <<pharmacokinetic_phenotype>>', 'CYP 3 A 4 <<gene_or_protein>>', 'CYP 3 A 4 induction <<phenotype>>', 'RTV <<chemical>>'],
                    'pred_entities' : ['Phenytoin <<chemical>>', 'LPV <<chemical>>', 'LPV clearance <<pharmacokinetic_phenotype>>', 'CYP 3 A 4 <<gene_or_protein>>', 'RTV <<chemical>>'] 

'sentence': Modulation of 5 - HT neurons in the dorsalraphe nucleus by GABA , glutamate and CRF profoundly regulate aggressive behaviors .,
                    'spans': [([0, 1, 2, 3, 4, 5], '<<phenotype>>'), ([2, 3, 4], '<<chemical>>'), ([11], '<<chemical>>'), ([13], '<<chemical>>'), ([15], '<<chemical>>'), ([18, 19], '<<phenotype>>')],
                    'pred_spans': [([2, 3, 4], '<<gene_or_protein>>'), ([11], '<<chemical>>'), ([13], '<<chemical>>'), ([15], '<<gene_or_protein>>'), ([18, 19], '<<phenotype>>')],
                    'entities' : ['Modulation of 5 - HT neurons <<phenotype>>', '5 - HT <<chemical>>', 'GABA <<chemical>>', 'glutamate <<chemical>>', 'CRF <<chemical>>', 'aggressive behaviors <<phenotype>>'],
                    'pred_entities' : ['5 - HT <<gene_or_protein>>', 'GABA <<chemical>>', 'glutamate <<chemical>>', 'CRF <<gene_or_protein>>', 'aggressive behaviors <<phenotype>>'] 

'sentence': A phase I study of selumetinib ( AZD 6244 / ARRY - 142866 ) , a MEK 1 / 2 inhibitor , in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer .,
                    'spans': [([5], '<<chemical>>'), ([5, 22, 23, 24, 25], '<<chemical>>'), ([7, 8], '<<chemical>>'), ([10, 11, 12], '<<chemical>>'), ([16, 17, 18, 19], '<<gene_or_protein>>'), ([16, 17, 18, 19, 20], '<<chemical>>'), ([25], '<<chemical>>'), ([27, 28, 29], '<<disease>>'), ([31], '<<gene_or_protein>>'), ([31, 32], '<<limited_variation>>'), ([31, 32, 33, 34], '<<disease>>')],
                    'pred_spans': [([5], '<<chemical>>'), ([5, 6, 7, 8, 9, 10, 11, 12, 13], '<<chemical>>'), ([16, 17, 18, 19], '<<gene_or_protein>>'), ([16, 17, 18, 19, 20], '<<chemical>>'), ([25], '<<chemical>>'), ([27, 28, 29], '<<disease>>'), ([31], '<<gene_or_protein>>'), ([31, 32], '<<limited_variation>>'), ([31, 32, 33, 34], '<<disease>>')],
                    'entities' : ['selumetinib <<chemical>>', 'selumetinib in combination with cetuximab <<chemical>>', 'AZD 6244 <<chemical>>', 'ARRY - 142866 <<chemical>>', 'MEK 1 / 2 <<gene_or_protein>>', 'MEK 1 / 2 inhibitor <<chemical>>', 'cetuximab <<chemical>>', 'refractory solid tumors <<disease>>', 'KRAS <<gene_or_protein>>', 'KRAS mutant <<limited_variation>>', 'KRAS mutant colorectal cancer <<disease>>'],
                    'pred_entities' : ['selumetinib <<chemical>>', 'selumetinib ( AZD 6244 / ARRY - 142866 ) <<chemical>>', 'MEK 1 / 2 <<gene_or_protein>>', 'MEK 1 / 2 inhibitor <<chemical>>', 'cetuximab <<chemical>>', 'refractory solid tumors <<disease>>', 'KRAS <<gene_or_protein>>', 'KRAS mutant <<limited_variation>>', 'KRAS mutant colorectal cancer <<disease>>'] 

'sentence': These pharmacokinetic parameters were also investigated with respect to the CYP 2 D 6 polymorphism , i . e . via dextromethorphan phenotyping of 9 subjects , 3 subjects were poor metabolizers , and 6 extensive metabolizers .,
                    'spans': [([1, 2], '<<pharmacokinetic_phenotype>>'), ([10, 11, 12, 13], '<<gene_or_protein>>'), ([10, 11, 12, 13, 14], '<<limited_variation>>'), ([21], '<<chemical>>'), ([21, 22], '<<phenotype>>'), ([30, 31], '<<pharmacokinetic_phenotype>>'), ([35, 36], '<<pharmacokinetic_phenotype>>')],
                    'pred_spans': [([1, 2], '<<pharmacokinetic_phenotype>>'), ([10, 11, 12, 13], '<<gene_or_protein>>'), ([10, 11, 12, 13, 14], '<<limited_variation>>'), ([21], '<<chemical>>'), ([30, 31], '<<pharmacokinetic_phenotype>>'), ([35, 36], '<<pharmacokinetic_phenotype>>')],
                    'entities' : ['pharmacokinetic parameters <<pharmacokinetic_phenotype>>', 'CYP 2 D 6 <<gene_or_protein>>', 'CYP 2 D 6 polymorphism <<limited_variation>>', 'dextromethorphan <<chemical>>', 'dextromethorphan phenotyping <<phenotype>>', 'poor metabolizers <<pharmacokinetic_phenotype>>', 'extensive metabolizers <<pharmacokinetic_phenotype>>'],
                    'pred_entities' : ['pharmacokinetic parameters <<pharmacokinetic_phenotype>>', 'CYP 2 D 6 <<gene_or_protein>>', 'CYP 2 D 6 polymorphism <<limited_variation>>', 'dextromethorphan <<chemical>>', 'poor metabolizers <<pharmacokinetic_phenotype>>', 'extensive metabolizers <<pharmacokinetic_phenotype>>'] 

'sentence': RESULTS : Two single - nucleotide polymorphisms were significantly associated with alcohol dependence in European Americans using the Nyholt corrected p value of . 007 : rs 886003 ( b = - . 212 , p = . 0002 ) and rs 17862325 ( b = - . 234 , p < . 0001 ) , but not in African Americans , likely because of the lower power to detect association in this group .,
                    'spans': [([3, 4, 5, 6], '<<limited_variation>>'), ([11], '<<chemical>>'), ([11, 12], '<<disease>>'), ([26, 27], '<<limited_variation>>'), ([41, 42], '<<limited_variation>>')],
                    'pred_spans': [([3, 4, 5, 6], '<<limited_variation>>'), ([11], '<<chemical>>'), ([11, 12], '<<disease>>'), ([26, 27], '<<limited_variation>>'), ([41, 42], '<<limited_variation>>')],
                    'entities' : ['single - nucleotide polymorphisms <<limited_variation>>', 'alcohol <<chemical>>', 'alcohol dependence <<disease>>', 'rs 886003 <<limited_variation>>', 'rs 17862325 <<limited_variation>>'],
                    'pred_entities' : ['single - nucleotide polymorphisms <<limited_variation>>', 'alcohol <<chemical>>', 'alcohol dependence <<disease>>', 'rs 886003 <<limited_variation>>', 'rs 17862325 <<limited_variation>>'] 

'sentence': Nigrostriatal lesions alter oral dyskinesia and c - Fos expression induced by the serotonin agonist 1 - ( m - chlorophenyl ) piperazine in adult rats .,
                    'spans': [([0, 1], '<<phenotype>>'), ([3, 4], '<<disease>>'), ([6, 7, 8], '<<gene_or_protein>>'), ([6, 7, 8, 9], '<<phenotype>>'), ([13, 14], '<<chemical>>'), ([15, 16, 17, 18, 19, 20, 21, 22], '<<chemical>>')],
                    'pred_spans': [([0, 1], '<<genomic_variation>>'), ([3, 4], '<<disease>>'), ([6, 7, 8], '<<gene_or_protein>>'), ([6, 7, 8, 9], '<<phenotype>>'), ([13, 14], '<<chemical>>'), ([15, 16, 17, 18, 19, 20, 21, 22], '<<chemical>>')],
                    'entities' : ['Nigrostriatal lesions <<phenotype>>', 'oral dyskinesia <<disease>>', 'c - Fos <<gene_or_protein>>', 'c - Fos expression <<phenotype>>', 'serotonin agonist <<chemical>>', '1 - ( m - chlorophenyl ) piperazine <<chemical>>'],
                    'pred_entities' : ['Nigrostriatal lesions <<genomic_variation>>', 'oral dyskinesia <<disease>>', 'c - Fos <<gene_or_protein>>', 'c - Fos expression <<phenotype>>', 'serotonin agonist <<chemical>>', '1 - ( m - chlorophenyl ) piperazine <<chemical>>'] 

'sentence': Thus , antisense PKA RIalpha and CpG immunomer in combination work cooperatively and as tumor - targeted therapeutics to treat human cancer .,
                    'spans': [([2, 3, 4], '<<chemical>>'), ([2, 3, 4, 5, 6, 7, 8, 9], '<<chemical>>'), ([6, 7], '<<chemical>>'), ([14], '<<disease>>'), ([14, 15, 16, 17], '<<chemical>>'), ([21], '<<disease>>')],
                    'pred_spans': [([3, 4], '<<gene_or_protein>>'), ([6, 7], '<<chemical>>'), ([14], '<<disease>>'), ([21], '<<disease>>')],
                    'entities' : ['antisense PKA RIalpha <<chemical>>', 'antisense PKA RIalpha and CpG immunomer in combination <<chemical>>', 'CpG immunomer <<chemical>>', 'tumor <<disease>>', 'tumor - targeted therapeutics <<chemical>>', 'cancer <<disease>>'],
                    'pred_entities' : ['PKA RIalpha <<gene_or_protein>>', 'CpG immunomer <<chemical>>', 'tumor <<disease>>', 'cancer <<disease>>'] 

'sentence': The incidence and type of p 53 mutation did not differ significantly in patients with a history of phenacetin abuse , smoking or neither of these habits .,
                    'spans': [([5, 6], '<<gene_or_protein>>'), ([5, 6, 7], '<<limited_variation>>'), ([18], '<<chemical>>'), ([18, 19], '<<phenotype>>'), ([21], '<<phenotype>>')],
                    'pred_spans': [([5, 6], '<<gene_or_protein>>'), ([5, 6, 7], '<<limited_variation>>'), ([18], '<<chemical>>'), ([18, 19], '<<disease>>'), ([21], '<<phenotype>>')],
                    'entities' : ['p 53 <<gene_or_protein>>', 'p 53 mutation <<limited_variation>>', 'phenacetin <<chemical>>', 'phenacetin abuse <<phenotype>>', 'smoking <<phenotype>>'],
                    'pred_entities' : ['p 53 <<gene_or_protein>>', 'p 53 mutation <<limited_variation>>', 'phenacetin <<chemical>>', 'phenacetin abuse <<disease>>', 'smoking <<phenotype>>'] 

'sentence': The effect was influenced by CYP 3 A 5 polymorphism , although the tacrolimus variability itself was not determined by the CYP 3 A 5 polymorphism .,
                    'spans': [([5, 6, 7, 8], '<<gene_or_protein>>'), ([5, 6, 7, 8, 9], '<<limited_variation>>'), ([13], '<<chemical>>'), ([13, 14], '<<pharmacodynamic_phenotype>>'), ([21, 22, 23, 24], '<<gene_or_protein>>'), ([21, 22, 23, 24, 25], '<<limited_variation>>')],
                    'pred_spans': [([5, 6, 7, 8], '<<gene_or_protein>>'), ([5, 6, 7, 8, 9], '<<limited_variation>>'), ([13], '<<chemical>>'), ([13, 14], '<<pharmacodynamic_phenotype>>'), ([21, 22, 23, 24], '<<gene_or_protein>>'), ([21, 22, 23, 24, 25], '<<limited_variation>>')],
                    'entities' : ['CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 polymorphism <<limited_variation>>', 'tacrolimus <<chemical>>', 'tacrolimus variability <<pharmacodynamic_phenotype>>', 'CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 polymorphism <<limited_variation>>'],
                    'pred_entities' : ['CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 polymorphism <<limited_variation>>', 'tacrolimus <<chemical>>', 'tacrolimus variability <<pharmacodynamic_phenotype>>', 'CYP 3 A 5 <<gene_or_protein>>', 'CYP 3 A 5 polymorphism <<limited_variation>>'] 

'sentence': HPMA copolymer bound adriamycin overcomes MDR 1 gene encoded resistance in a human ovarian carcinoma cell line .,
                    'spans': [([0, 1, 2, 3], '<<chemical>>'), ([3], '<<chemical>>'), ([5, 6], '<<gene_or_protein>>'), ([5, 6, 7, 8, 9], '<<phenotype>>'), ([13, 14], '<<disease>>')],
                    'pred_spans': [([0], '<<chemical>>'), ([0, 1, 2, 3], '<<chemical>>'), ([3], '<<chemical>>'), ([5, 6], '<<gene_or_protein>>'), ([5, 6, 7, 8, 9], '<<pharmacodynamic_phenotype>>'), ([13, 14], '<<disease>>')],
                    'entities' : ['HPMA copolymer bound adriamycin <<chemical>>', 'adriamycin <<chemical>>', 'MDR 1 <<gene_or_protein>>', 'MDR 1 gene encoded resistance <<phenotype>>', 'ovarian carcinoma <<disease>>'],
                    'pred_entities' : ['HPMA <<chemical>>', 'HPMA copolymer bound adriamycin <<chemical>>', 'adriamycin <<chemical>>', 'MDR 1 <<gene_or_protein>>', 'MDR 1 gene encoded resistance <<pharmacodynamic_phenotype>>', 'ovarian carcinoma <<disease>>'] 

'sentence': The diallyl disulfide - mediated inhibition of H - ras oncogene transformed tumor growth correlated with the inhibition of p 21 ( H - ras ) membrane association .,
                    'spans': [([1, 2], '<<chemical>>'), ([1, 2, 3, 4, 5, 6, 7, 8, 9, 10], '<<pharmacodynamic_phenotype>>'), ([5, 6, 7, 8, 9, 10], '<<pharmacodynamic_phenotype>>'), ([7, 8, 9], '<<gene_or_protein>>'), ([12], '<<disease>>'), ([12, 13], '<<phenotype>>'), ([17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], '<<phenotype>>'), ([19, 20], '<<gene_or_protein>>'), ([22, 23, 24], '<<gene_or_protein>>')],
                    'pred_spans': [([1, 2], '<<chemical>>'), ([5, 6, 7, 8, 9, 10], '<<phenotype>>'), ([7, 8, 9], '<<gene_or_protein>>'), ([7, 8, 9, 10, 11, 12, 13], '<<phenotype>>'), ([12], '<<disease>>'), ([19, 20], '<<gene_or_protein>>'), ([19, 20, 21, 22, 23, 24, 25, 26, 27], '<<phenotype>>'), ([22, 23, 24], '<<gene_or_protein>>')],
                    'entities' : ['diallyl disulfide <<chemical>>', 'diallyl disulfide - mediated inhibition of H - ras oncogene <<pharmacodynamic_phenotype>>', 'inhibition of H - ras oncogene <<pharmacodynamic_phenotype>>', 'H - ras <<gene_or_protein>>', 'tumor <<disease>>', 'tumor growth <<phenotype>>', 'inhibition of p 21 ( H - ras ) membrane association <<phenotype>>', 'p 21 <<gene_or_protein>>', 'H - ras <<gene_or_protein>>'],
                    'pred_entities' : ['diallyl disulfide <<chemical>>', 'inhibition of H - ras oncogene <<phenotype>>', 'H - ras <<gene_or_protein>>', 'H - ras oncogene transformed tumor growth <<phenotype>>', 'tumor <<disease>>', 'p 21 <<gene_or_protein>>', 'p 21 ( H - ras ) membrane association <<phenotype>>', 'H - ras <<gene_or_protein>>'] 

'sentence': The combination of erlotinib and bevacizumab prolongs PFS in patients with EGFR - mutant NSCLC .,
                    'spans': [([3], '<<chemical>>'), ([3, 4, 5], '<<chemical>>'), ([5], '<<chemical>>'), ([7], '<<phenotype>>'), ([11], '<<gene_or_protein>>'), ([11, 12, 13], '<<limited_variation>>'), ([11, 12, 13, 14], '<<disease>>')],
                    'pred_spans': [([1, 2, 3, 4, 5], '<<chemical>>'), ([3], '<<chemical>>'), ([5], '<<chemical>>'), ([7], '<<phenotype>>'), ([11], '<<gene_or_protein>>'), ([11, 12, 13], '<<limited_variation>>'), ([11, 12, 13, 14], '<<disease>>')],
                    'entities' : ['erlotinib <<chemical>>', 'erlotinib and bevacizumab <<chemical>>', 'bevacizumab <<chemical>>', 'PFS <<phenotype>>', 'EGFR <<gene_or_protein>>', 'EGFR - mutant <<limited_variation>>', 'EGFR - mutant NSCLC <<disease>>'],
                    'pred_entities' : ['combination of erlotinib and bevacizumab <<chemical>>', 'erlotinib <<chemical>>', 'bevacizumab <<chemical>>', 'PFS <<phenotype>>', 'EGFR <<gene_or_protein>>', 'EGFR - mutant <<limited_variation>>', 'EGFR - mutant NSCLC <<disease>>'] 

'sentence': After the screening of 860 healthy Finnish volunteers for the CES 1 c . 428 G > A ( p . Gly 143 Glu , rs 121912777 ) polymorphism , a pharmacokinetic study with 75 mg oseltamivir was carried out in c . 428 G > A carriers and noncarriers .,
                    'spans': [([10, 11], '<<gene_or_protein>>'), ([10, 11, 12, 13, 14, 15, 16, 17], '<<limited_variation>>'), ([19, 20, 21, 22, 23], '<<limited_variation>>'), ([25, 26], '<<limited_variation>>'), ([36], '<<chemical>>'), ([41, 42, 43, 44, 45, 46], '<<limited_variation>>')],
                    'pred_spans': [([10, 11], '<<gene_or_protein>>'), ([10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28], '<<limited_variation>>'), ([25, 26], '<<limited_variation>>'), ([31, 32, 33, 34, 35, 36], '<<pharmacokinetic_phenotype>>'), ([36], '<<chemical>>'), ([41, 42, 43, 44, 45, 46], '<<limited_variation>>')],
                    'entities' : ['CES 1 <<gene_or_protein>>', 'CES 1 c . 428 G > A <<limited_variation>>', 'p . Gly 143 Glu <<limited_variation>>', 'rs 121912777 <<limited_variation>>', 'oseltamivir <<chemical>>', 'c . 428 G > A <<limited_variation>>'],
                    'pred_entities' : ['CES 1 <<gene_or_protein>>', 'CES 1 c . 428 G > A ( p . Gly 143 Glu , rs 121912777 ) polymorphism <<limited_variation>>', 'rs 121912777 <<limited_variation>>', 'pharmacokinetic study with 75 mg oseltamivir <<pharmacokinetic_phenotype>>', 'oseltamivir <<chemical>>', 'c . 428 G > A <<limited_variation>>'] 

'sentence': Combination of fludarabine with SYK Inhibitor II or R 406 increased cytotoxicity compared with fludarabine therapy alone .,
                    'spans': [([0, 1, 2, 3, 4, 5, 6], '<<chemical>>'), ([0, 1, 2, 3, 8, 9], '<<chemical>>'), ([2], '<<chemical>>'), ([4], '<<gene_or_protein>>'), ([4, 5, 6], '<<chemical>>'), ([8, 9], '<<chemical>>'), ([11], '<<disease>>'), ([14], '<<chemical>>')],
                    'pred_spans': [([2], '<<chemical>>'), ([2, 3, 4, 5, 6], '<<chemical>>'), ([2, 3, 8, 9], '<<chemical>>'), ([4, 5, 6], '<<gene_or_protein>>'), ([8, 9], '<<chemical>>'), ([11], '<<pharmacodynamic_phenotype>>'), ([14], '<<chemical>>')],
                    'entities' : ['Combination of fludarabine with SYK Inhibitor II <<chemical>>', 'Combination of fludarabine with R 406 <<chemical>>', 'fludarabine <<chemical>>', 'SYK <<gene_or_protein>>', 'SYK Inhibitor II <<chemical>>', 'R 406 <<chemical>>', 'cytotoxicity <<disease>>', 'fludarabine <<chemical>>'],
                    'pred_entities' : ['fludarabine <<chemical>>', 'fludarabine with SYK Inhibitor II <<chemical>>', 'fludarabine with R 406 <<chemical>>', 'SYK Inhibitor II <<gene_or_protein>>', 'R 406 <<chemical>>', 'cytotoxicity <<pharmacodynamic_phenotype>>', 'fludarabine <<chemical>>'] 

'sentence': Possible involvement of CCT 5 , RGS 3 , and YKT 6 genes up - regulated in p 53 - mutated tumors in resistance to docetaxel in human breast cancers .,
                    'spans': [([3, 4], '<<gene_or_protein>>'), ([6, 7], '<<gene_or_protein>>'), ([10, 11], '<<gene_or_protein>>'), ([17, 18], '<<gene_or_protein>>'), ([17, 18, 19, 20], '<<limited_variation>>'), ([17, 18, 19, 20, 21], '<<disease>>'), ([23, 24, 25], '<<pharmacodynamic_phenotype>>'), ([25], '<<chemical>>'), ([28, 29], '<<disease>>')],
                    'pred_spans': [([3, 4], '<<gene_or_protein>>'), ([6, 7], '<<gene_or_protein>>'), ([10, 11], '<<gene_or_protein>>'), ([17, 18], '<<gene_or_protein>>'), ([17, 18, 19, 20], '<<limited_variation>>'), ([23, 24, 25], '<<pharmacodynamic_phenotype>>'), ([25], '<<chemical>>'), ([28, 29], '<<disease>>')],
                    'entities' : ['CCT 5 <<gene_or_protein>>', 'RGS 3 <<gene_or_protein>>', 'YKT 6 <<gene_or_protein>>', 'p 53 <<gene_or_protein>>', 'p 53 - mutated <<limited_variation>>', 'p 53 - mutated tumors <<disease>>', 'resistance to docetaxel <<pharmacodynamic_phenotype>>', 'docetaxel <<chemical>>', 'breast cancers <<disease>>'],
                    'pred_entities' : ['CCT 5 <<gene_or_protein>>', 'RGS 3 <<gene_or_protein>>', 'YKT 6 <<gene_or_protein>>', 'p 53 <<gene_or_protein>>', 'p 53 - mutated <<limited_variation>>', 'resistance to docetaxel <<pharmacodynamic_phenotype>>', 'docetaxel <<chemical>>', 'breast cancers <<disease>>'] 

'sentence': To reach an effective dose while avoiding adverse drug reactions ( ADRs ) , testing of CYP 2 D 6 genotype prior to carvedilol initiation may be considered .,
                    'spans': [([3, 4], '<<pharmacodynamic_phenotype>>'), ([7, 8, 9], '<<pharmacodynamic_phenotype>>'), ([11], '<<pharmacodynamic_phenotype>>'), ([16, 17, 18, 19], '<<gene_or_protein>>'), ([16, 17, 18, 19, 20], '<<limited_variation>>'), ([23], '<<chemical>>')],
                    'pred_spans': [([3, 4], '<<pharmacodynamic_phenotype>>'), ([7, 8, 9], '<<pharmacodynamic_phenotype>>'), ([11], '<<pharmacodynamic_phenotype>>'), ([16, 17, 18, 19], '<<gene_or_protein>>'), ([16, 17, 18, 19, 20], '<<limited_variation>>'), ([23], '<<chemical>>')],
                    'entities' : ['effective dose <<pharmacodynamic_phenotype>>', 'adverse drug reactions <<pharmacodynamic_phenotype>>', 'ADRs <<pharmacodynamic_phenotype>>', 'CYP 2 D 6 <<gene_or_protein>>', 'CYP 2 D 6 genotype <<limited_variation>>', 'carvedilol <<chemical>>'],
                    'pred_entities' : ['effective dose <<pharmacodynamic_phenotype>>', 'adverse drug reactions <<pharmacodynamic_phenotype>>', 'ADRs <<pharmacodynamic_phenotype>>', 'CYP 2 D 6 <<gene_or_protein>>', 'CYP 2 D 6 genotype <<limited_variation>>', 'carvedilol <<chemical>>'] 

'sentence': AIM : To evaluate bacterial cytosine deaminase ( bCD ) mutant D 314 A and 5 - fluorocytosine ( 5 - FC ) for treatment of colon cancer in a mouse model .,
                    'spans': [([5, 6], '<<gene_or_protein>>'), ([5, 6, 7, 8, 9, 10, 11, 12, 13], '<<limited_variation>>'), ([8], '<<gene_or_protein>>'), ([15, 16, 17], '<<chemical>>'), ([19, 20, 21], '<<chemical>>'), ([26, 27], '<<disease>>')],
                    'pred_spans': [([4, 5, 6], '<<gene_or_protein>>'), ([4, 5, 6, 7, 8, 9, 10], '<<limited_variation>>'), ([8], '<<gene_or_protein>>'), ([11, 12, 13], '<<chemical>>'), ([15, 16, 17], '<<chemical>>'), ([19, 20, 21], '<<chemical>>'), ([26, 27], '<<disease>>')],
                    'entities' : ['cytosine deaminase <<gene_or_protein>>', 'cytosine deaminase ( bCD ) mutant D 314 A <<limited_variation>>', 'bCD <<gene_or_protein>>', '5 - fluorocytosine <<chemical>>', '5 - FC <<chemical>>', 'colon cancer <<disease>>'],
                    'pred_entities' : ['bacterial cytosine deaminase <<gene_or_protein>>', 'bacterial cytosine deaminase ( bCD ) mutant <<limited_variation>>', 'bCD <<gene_or_protein>>', 'D 314 A <<chemical>>', '5 - fluorocytosine <<chemical>>', '5 - FC <<chemical>>', 'colon cancer <<disease>>'] 

'sentence': PMH therapy was not significantly associated with the MSI - H , CIMP - positive or BRAF - mutated CRC subtypes .,
                    'spans': [([0], '<<chemical>>'), ([8, 9, 10], '<<genomic_factor>>'), ([8, 9, 10, 19], '<<disease>>'), ([12, 13, 14], '<<phenotype>>'), ([12, 13, 14, 19], '<<disease>>'), ([16], '<<gene_or_protein>>'), ([16, 17, 18], '<<limited_variation>>'), ([16, 17, 18, 19], '<<disease>>'), ([19], '<<disease>>')],
                    'pred_spans': [([0], '<<chemical>>'), ([8, 9, 10], '<<gene_or_protein>>'), ([8, 9, 10, 14], '<<phenotype>>'), ([12], '<<gene_or_protein>>'), ([12, 13, 14], '<<phenotype>>'), ([16], '<<gene_or_protein>>'), ([16, 17, 18, 19], '<<limited_variation>>'), ([19], '<<disease>>')],
                    'entities' : ['PMH <<chemical>>', 'MSI - H <<genomic_factor>>', 'MSI - H CRC <<disease>>', 'CIMP - positive <<phenotype>>', 'CIMP - positive CRC <<disease>>', 'BRAF <<gene_or_protein>>', 'BRAF - mutated <<limited_variation>>', 'BRAF - mutated CRC <<disease>>', 'CRC <<disease>>'],
                    'pred_entities' : ['PMH <<chemical>>', 'MSI - H <<gene_or_protein>>', 'MSI - H positive <<phenotype>>', 'CIMP <<gene_or_protein>>', 'CIMP - positive <<phenotype>>', 'BRAF <<gene_or_protein>>', 'BRAF - mutated CRC <<limited_variation>>', 'CRC <<disease>>'] 

True contiguous count : 484. Contiguous recall : 0.7520661157024794
True discontinuous count : 41. Discontinuous recall : 0.2926829268292683
Estimated contiguous precision : 0.7443762781186094
Estimated discontinuous precision : 0.34285714285714286
Estimated 35 predictions on discontinuous entities, 
23 of them were approximated from candidate spans
Estimated 489 predictions on continuous entities, 
        70 of them were approximated from candidate spans,
        55 were considered discontinuous by default